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Abstract 
Trichosanthin (TCS) is a purified plant protein which belongs to the family of 
Type I ribosome inactivating protein (RIP). It has a broad spectrum of 
pharmacological activities and one of these is its potent anti-HIV activity in vitro. 
Trichosanthin is a small molecular weight protein and therefore excessive renal loss 、 
and short plasma half-life is anticipated. It was shown in some clinical studies that it 
was also a potent antigen. Therefore, the aim of this project is to synthesis dextran-
trichosanthin (DX-TCS) conjugate which combines the properties of prolonged 
circulatory half-life with lowered antigenicity • In this study, the dialdehyde method 
was used to couple TCS to dextran T40 and the pharmacokinetic, biological and 
immunological activities of DX-TCS compared with the native compound . 
A sensitive radioimmunoassay was developed to detect plasma and urine TCS 
in the nanogram range. Trichosanthin was successfully coupled to dextran T40 by a 
dialdehyde method using TCS to dextran molar ratio of 1:25. Complete coupling was 
confirmed by gel filtration chromatography and the conjugate was stable upon storage 
for up to six months at 4°C. 
In the pharmacokinetic study of the single i.v. injection of TCS (0.75 mg/kg) 
« 
into normal and renal arterial ligated rats, the plasma clearance was 4.78 土 0.57 
ml/min and 0.22 士 0.02 ml/min respectively. Injection of DX-TCS resulted in a even 
V 
lower plasma clearance of 0.06 士 0.04 ml/min and no TCS activity was detected in 
、 urine. Despite the short half-life of TCS and the major role of kidney in elimination, 
recovery of TCS in urine was only 0.38 土 0.05%. Circumstantial evidence supported 
that TCS was reabsorbed by renal tubular cells. Firstly, the percentage urine recovery 
of TCS could be increased in a dose dependent manner and could be up to 40% when 
12 mg/kg TCS was injected, suggesting saturation of the reabsorption process. 
Secondly, simultaneously infusion of other filterable proteins such as lysozyme and 
haemoglobin increased TCS excretion, implying the utilization of the common 
endocytotic process for low molecular weight proteins. Furthermore, this reabsorption 
process also damaged the renal tubular cells as manifested by the depression of 
glomerular filtration rate after TCS injection. This renal toxicity was abolished when 
DX-TCS was used or by simultaneous lysozyme infusion. 
The biological activities of DX-TCS were evaluated by different bioassays. 
Firstly, DX-TCS, like its parent compound induces mid-term abortion with decreased 
potency. A dose of 0.02 mg/25 g TCS induced 100% abortion while 0.4 mg/25 g 
DX-TCS was needed to achieve the same effect. In addition, a dose of 0.1 mg/25 g 
TCS was toxic and produced 33% mortality rate while 4 times as much DX-TCS did 
not cause any death. Secondly, the immunosuppressive ability of TCS was 
maintained. DX-TCS suppressed the Con A and PHA but not LPS mitogenic effect 
with decreased potency. Thirdly, both TCS and DX-TCS exhibited cytostatic effect 
on PUS and hepatoma tumour cells with the ID50 at the levels of 5 A^g/ml and 30 
, - "•. + _ 
/xg/ml for PUS tumour cells and 10 /xg/ml and 50 /.g/ml for the hepatoma cells. 
In the immunogenicity study of TCS and DX-TCS, it was found that the 
conjugate elicited less IgG and IgE against the molecule than that of TCS using 
enzyme linked immunosorbent assay (ELISA). 
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Chapter 1: Introduction 
Trichosanthin (TCS) 
1. Source and Purification 
Trichosanthin (TCS)(夭花弟分麥合）is a plant derived protein that is purified 
from the root tubers of the Chinese medicinal plant Trichosanthes Mrilowii 
(Curcubitaceae). It has been identified as the active ingredient of the Chinese 
medicine, Tian Hua Fen (1,2,3). This medicine was described as early as the 14也 
century in China by Li Shi-Zhen in the book named Compendium of Materia Medica 
It is used traditionally in folk medicine since ancient times to induce 
menstruation and to expel fetal membranes (4). Nowadays, it is still being used in 
China to induce abortions, particularly those in the second trimester (5,6)，and to treat 
choriocarcinoma, hydatidiform moles, and ectopic pregnancy (6,7). 
The multistep purification procedure of TCS involved homogenization of root 
tubers, acetone fractionation, ammonium sulphate precipitation, ion-exchange 
chromatography on CM-sepharose and preparative agarose electrophoresis. The 
homogeneity was demonstrated by immunoelectrophoresis and SDS-polyacrylamide 
gel electrophoresis (8). 
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2. Physicochemical Properties 
Trichosanthin is a single polypeptide chain with a molecular mass of 26 kDa; 
containing no carbohydrates, phosphorous and cysteine residue. It is basic protein 
with an isoelectric point of 9.4 (9,10). The complete amino acid sequence of TCS 
was first reported by Wang in 1985 (9)，that it consisted of 234 amino acid residues. 
Later in 1989，Collins et al reported a modified version which was substantially 
different from the previous one (11). It is quite clear now that TCS is synthesized 
first as a prepro-protein consisting of 289 amino acids. The first 23 residues comprise 
a putative signal peptide. The last 19 residues comprise a carboxyl extension that has 
never been reported to be associated with the mature protein and hence may be 
processed in the endoplasmic reticulum or Golgi apparatus of cells producing TCS. 
The mature protein thus consists of 247 amino acids. 
Study of its secondary structure by circular dichroism showed that the TCS 
molecule consisted of about 30 % helix，40-60 % B-sheet and no iMums (12) • Its three-
% 
dimensional structure had been determined by X-ray crystallography (13) and the gene 
encoding TCS was isolated and the DNA sequence determined (14,15). 
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3. Biological Properties 
I . Ribosome inactivating property 
Ribosome inactivating proteins (RIPs) is a large and widely distributed class 
of plant proteins that are potent inhibitors of eukaryotic protein synthesis. They are 
usually present in high concentrations but their biological significance in plants is still 
puzzling to plant physiologists (16，17). 
There are 2 types of RIPs: the single-chained Type I proteins (e.g saporin) and 
the double-chained Type II proteins (e.g. ricin, abrin). Type I RIPs are single 
polypeptide chain with molecular mass of about 30 kDa and strongly basic (pi often 
> 9.5). Type II RIPs consists of a ribosome-inactivating A chain with molecular 
mass of about 30 kDa, pi between 4.8 and 8, linked by a single disulphide bond to 
a B chain which exhibits lectin-like properties. The latter subunit binds the protein 
to D-galactose present on the eukaryotic cell surface. Thus, the B chain facilitates 
the entry of the A chain into the cytosol where it exerts the ribosome inactivating 
action. The molecular mass of the whole molecule is typically in the order of 60 kDa. 
In the past few years, there was a lot of evidences to suggest that TCS is 
actually a Type I ribosome inactivating protein. Trichosanthin has potent activity in 
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inhibiting protein synthesis in a reticulocyte lysate system (18,19,20). Zhang and 
Wang revealed a remarkable sequence homology of 56% between TCS and ricin A 
chain when both identical and conservative residues are considered (21). The 
structural similarities of the ricin A chain and TCS were further demonstrated by 
circular dichroism analysis (22). There was also tertiary structural similarity between 
TCS and ricin A chain (23,24). Furthermore, based on the sequence homologies 
between these two proteins, the primary sequence of TCS was fitted to the backbone 
structure for ricin A chain to generate energy-minimized molecular model (11). 
As demonstrated by the A chain of ricin, the action of RIPs is on the 60 S 
ribosomal subunit. It catalytically hydrolyses a single N-glycosidic bond of the 
adenosine residue at position 4324 (A-4324) in 28 S rRNA of rat liver. After 
releasing the adenine from the rRNA, the formation of the complex between 
ribosome, elongation-factor-2 (EF-2) and GTP which is the first event during protein 
synthesis is inhibited. Consequently, this would lead to a rapid shut down of protein 
synthesis (25,26,27,28). 
« 
n . Abortifacient property 
Tian Hua Fen, the root tubers of Trichosanthes kirilowii has been used in 
conjunction with seven to eight other Chinese herbs to induce abortion since ancient 
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times (2). Later in 1971，"Radix trichosanthis", a traditional Chinese drug extracted 
from the root tubers of Tnchosanthes kirilowii was introduced in China for induction 
of midtrimester abortion with a recommended single doses of 5 to 12.5mg (29). 
Generally, these doses are effective for the intended clinical indication and well 
tolerated. The active component of Radix trichosanthis was subsequently identified 
as the plant protein TCS. 
Mid-term abortifacient activity of TCS was also studied in several mammalian 
models including mice, rabbits and monkeys (3,30,31). Its mode of action was 
examined extensively. Xiong et al (32) showed that TCS exerted direct and specific 
injurious effects on human syncytiotrophoblasts. The abortifacient action of TCS was 
therefore postulated to be mediated through its direct specific action on placental 
trophoblasts. It was suggested that TCS may damage the syncytiotrophoblasts of the 
placental villi，releasing clumps of disintegrating cells into the circulation. This 
hinders placenta blood circulation, leading to tissue necrosis and eventually abortion 
(33,34,35). 
« 
Apart from mid-term abortifacient activity, TCS was also used to terminate 
early pregnancies (5,6). Similar effect was also found in mouse (36). The protein 
exerts its effect by blocking the hatching of embryos form the zona pellucida, 
decreasing the incidence of successful attachment of the blastocyst, reducing the 
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trophoblast outgrowth and disrupting the development of inner cell mass. Therefore, 
it does not only result in the retardation of the development of the embryos but also 
prevent their implantation, leading to the termination of early pregnancy. 
III. Anti-tumour activity 
Trichosanthin was shown to be active against the abnormal growth of 
trophoblastic cells in hydatidiform mole, malignant mole and choriocarcinoma, both 
in vivo (37) and in vitro (39,40,41,42,43). This action is believed to be related to its 
ribosome inactivating activity and the preferential cytotoxicity to certain types of cells 
such as the trophoblasts and trophoblast-derived cells in the above examples. 
Clinically, trichosanthin has been used for the treatment of trophoblastic 
tumours. Clinical reports from hospitals in mainland China showed high cure rates 
(90-98%) in malignant moles using TCS alone or in combination with other 
chemotherapeutic drugs, herbal medicines and surgery (37,100). The prognosis of 
hydatidiform mole was better than choriocarcinoma when using TCS for treatment of 
the cancer patients. 
In recent years, the possibility of producing immunotoxins (or antibody-
conjugated toxins) has been studied extensively (44,45). This is of considerable 
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interest because such molecules can be selectively targeted to a particular cell type, 
such as cancer cells. In fact, TCS was successfully conjugated to an antihepatoma 
monoclonal antibody. The immunotoxin shows potent and quite specific antihepatoma 
activity in vitro (46). Even though the therapeutic potential of immunotoxins is 
attractive, there are stiU some problems which require unique solutions before the 
consideration for entry into clinical trials. These includes the stability and 
biodistribution of conjugates in vivo, the specific reactivity of the conjugates to the 
targeting tumours, the access and localization of conjugates in the tumour and the 
immunogenicity of the immunotoxins. 
IV. Anti-HIV activities 
Recently, TCS (also called GLQ 223 by the authors) was first shown by 
McGrath in 1989 to have potent activity against HIV-1 infected cells in vitro (47). 
Trichosanthin inhibits HIV-1 replication in both acutely infected T-lymphoblastoid 
cells and in chronically infected macrophages. In acutely infected T-lymphoblastoid 
cells, treatment with TCS produced concentration-dependent inhibition of HIV 
replications as determined by a reduction in HIV protein (p24 levels). Moreover, TCS 
treatment also resulted in a selective proportional decrease in the amount of viral 
RNA present in the treated cells relative to total cellular RNA. On the other hand, 
TCS treatment of monocyte/macrophages chronically infected with HIV in vitro 
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completely abrogated the HIV antigen expression and ultimately killed the HIV-
infected cells in cultures. The mechanism of the selective inhibitory activity of TCS 
is still unknown. Although it is a type I ribosome inactivating protein, it has not been 
established whether the anti-HIV activity is directly related to this property. 
Furthermore, it seems that the viral RNA synthesis was more suspectable to TCS and 
therefore perhaps suggesting a possible selective effect of the drug on viral nucleic 
acid synthesis, processing or stability (47,48,49). 
Due to the reported anti-HIV activity of TCS, it becomes an interesting 
candidate as a potential therapeutic agent against HIV infection. Clinical studies are 
actively underway. In fact, both phase I and phase II clinical study have been 
,completed to access the safety, pharmacokinetics and tolerance of TCS in AIDS 
patients. The most serious problem was the numerous side effects seen with this 
compound such as headache, myalgia, fevers, fatigue and neurotoxicity. Therefore, 
the potential use of TCS clinically as anti-HIV drug still requires careful further 
evaluation (50,51). 
4. Immunological Properties 
I. Immunosuppressive effect 
Trichosanthin can be considered as an agent that modulate the immune system 
8 
/ 
by suppressing a variety of immune reactions. For example, it inhibits the mitogen-
induced lymphoproHferative response, the production of IL-2 by Con A activated 
splenocytes and the effector functions of macrophages such as phagocytic activity in 
vitro. It also depresses in vivo reaction such as delayed-type hypersensitivity to sheep 
rat blood cell (SRBC) (53,54). 
I I . Antigenicity and allergenicity 
Trichosanthin is a plant protein which has potential immunological side effects. 
This may hinder the extensive pharmacological application of this protein. Indeed, 
anaphylaxis is observed occasionally in patients treated with the purified protein 
(93，94). Experimental results in animal model indicate that injection of TCS with 
albumin hydroxide as adjuvant into mice would result in the production of high titre 
of IgE. 
Studies on its immunological characteristics has, shown 16 monoclonal 
antibodies including 5 IgE, 8 IgGl, 1 IgG3，1 IgA and 1 IgM. Competitive binding 
assay further indicates that these 16 monoclonal antibodies fall into 4 groups of 
antigenic determinants/epitopes (56). 
( 
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5. DNase-like activity 
It was recently demonstrated that TCS possess DNase-like activity., 
Trichosanthin was able to cleave the supercoiled double-stranded DNA to produce 
nicked circular and linear DNA. Whether this interesting phenomena of TCS on 
different forms of DNA substrates is relate to the mechanism of anti-HIV activity 
remains to be explored (52). 
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Dextran Conjugates 
1. Advantages of synthesizing conjugates 
There are many parameters such as half-life that can affect the usefulness of 
a biologically active component as a therapeutic agent. Factors affecting half-life of 
a drug in the host includes enzymes degradation, renal loss and poor chemical 
stability. Therapeutic use of a drug with short half-life is limited by the need to give 
frequent doses to the patient. It is inconvenient to the patients and large amount of 
drugs are required. This will create problem especially with drugs that are potent 
antigen. Repeated injections of these drugs to the patients would increase the risk of 
a hypersensitivity reaction. 
As a consequence, in the past few decades, many attempts have been tried to 
increase the biological half-life and reduce the antigenicity of the drug through 
chemical modification. One of the approaches has involved coupling the drug to a 
% 
carrier such as homologous albumin (95)，polyethylene glycol (96) or dextran (57,58) 
etc.. Among these compounds which can be employed as a possible carrier of 
pharmacological substances is the polysaccharides, dextran which seems to possess 
some of the necessary qualifications that will be explained later. The exact 
mechanisms of the enhanced plasma half-life and reduced antigenicity of the protein 
by the dextran carrier are still unknown. However, it has been postulated that the 
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effect may be due to the protection against degradation or removal of the intact 
protein through changes in the electrostatic charge of the conjugated protein (59), or 
the increase in relative mass (60). Increase in molecular mass would also allow the 
protein to escape form glomerular filtration. Reduced immunogenicity may also 
occurred due to the blocking of the antigenic determinants on the molecule 
(61,62,63). 
- - - -
2. Dextran as carrier 
Dextran is a high-molecular-weight polymer of D-glucose linked 
predominantly by a-D (1—6) linkages (64). It is synthesized by enzymes called 
glycosyltransferases on the cell surface of certain lactic acid bacteria. Several 
organisms produce dextrans but only Leuconostoc mesenteroides and L, dextranicum 
(Lactobacteriaceae) have been used commercially. 
Dextrans have several characteristics that make it a suitable drug carriers. 
Firstly, it is soluble in water. Secondly, it can be obtained in a wide range of 
molecular sizes. Dextrans with average molecular weights of 1000，5000, 40,000, 
75,000, 110,000, 700,000, and even more are available. Thirdly, it can be activated 
by various chemical methods to react to form defined and stable compounds. Lastly, 
it lacks any significant toxicity or organ or cellular tropism. In fact, dextrans with 
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molecular weight of 40,000 and 70,000 are used clinically as plasma volume 
expander. Therefore, dextrans can be considered as essentially harmless except some 
higher molecular weight dextrans which are immunogenic in human (65). 
3. Strategy for producing dextran conjugates 
For the synthesis of any conjugates, an ideal conjugation method should (a) 
have minimum interference with the activity of the parent compound; (b) allow high 
incorporation, yet be sufficiently controllable to be tailored to the production of 
homogeneous conjugates with optimal carrier to drug ratios; (c) avoid formation of 
homopolymer of either the carrier or drug; (d) avoid aggregation of the conjugate; 
and (e) be technically straightforward and reproducible. 
Numerous methods have been developed to activate dextran for coupling to 
protein molecule. For example, oxidation of the polysaccharide by periodate to form 
polyaldehyde dextran; preparation of an azide dextran; activation by cyanogen halides 
or organic cyanates to form imidocarbonate dextrans and preparation of bromo- or 
chlorohydroxypropyl dextran, through a reaction with bromo- or chloropropyl 
epoxide. All these methods allow us to synthesize drug-linked polysaccharides with 
a suitable molecular weight. After the reaction, the conjugates can be purified from 
the unreacted drug by various biochemical methods such as column chromatography 
13 
4. Examples of dextran-protein conjugates 
In the search for a better blood substitute, the first dextran-protein conjugate 
(dextran-haemoglobin complex) was synthesized. Coupling of haemoglobin to dextran 
successfully prevent its filtration through the kidneys and thus prolong the half-life 
of haemoglobin in the circulation. The biological activity of transporting oxygen was 
slightly altered and the complex was found to be non-immunogenic in homologous 
species (66,67,68,69). 
Another example is the coupling of microbial enzymes such as asparaginase 
to dextran. Microbial enzymes offer several possibilities for application in cancer 
chemotherapy. Continuous depletion of specific amino acids from body fluids by 
enzymatic action has been proved to be a therapeutic approach demonstrating a high 
degree of specificity for the neoplasm. An example is the treatment of acute 
lymphoblastic leukemias by the enzyme asparaginase (70). Unfortunately, microbial 
enzymes usually have a relatively short half-life of less than 10 hours. Some are even 
shown to be immunogenic in human (71). Therefore, modification of the microbial 
enzymes by chemically couple to dextran has been investigated in the past ten years. 
According to this principle, soluble dextran-asparaginase conjugates was synthesized. 
The plasma half-life was shown to be increased and the antigen reactivity was reduced 
(71,72). 
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Other examples include the conjugation of carboxypeptidase G (57,73,74), 
adenosine deaminase (75) and arginase (57) to soluble dextran. Similarly, their plasma 
half-lives were successfully prolonged. As a result, coupling of protein to dextran is 
a possible way to improve the therapeutic usage of a drug and this would allow a 
wider clinically application of the modified drug. 
- . . ”‘ • 
5. Dextran-trichosanthin conjugate 
Although the plant protein trichosanthin has wide spectrum of pharmacological 
actions such as mid-term abortifacient activity, anti-tumor and anti-HIV activities etc.， 
it is still limited in use due to some of its characteristics such as short half-life, 
immunogenicity and its toxicity. Trichosanthin is a low molecular weight protein with 
molecular weight of only 26 kDa. Therefore, a short plasma half-life is anticipated 
since it can be rapidly excreted by the kidneys. In order to overcome these 
limitations, trichosanthin is covalently couple to dextran T40 with a molecular weight 
of 40 kDa. 
The aim of this study is to modify the protein, trichosanthin by linking it to 
dextran so as to expand the molecular size of it. This would retard its filtration 
through the kidney and result in a longer half-life. At the same time, antigenicity of 
this protein may also be reduced. 
15 
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Chapter 2: Methodology 
1. Preparation of Trichosanthin and its antiserum 
Trichosanthin was purified from the root tubers of Trichosanthes kirilowii 
obtained from Kwansi Province, China as described in the reference (8). Briefly, the 
root tubers were first cut into small pieces, homogenized with 0.9% normal saline 
and filtered to give a crude extract which was then subjected to acetone fractionation, 
giving rise to the AP4 fraction. It was further purified by ammonium sulphate 
precipitation to remove the contaminant and the supernatant designated S40 was 
obtained. This resulting fraction was then applied to a CM-Sepharose CL-6B column 
and purified TCS could be obtained first by isocratic elution with 0.05 M phosphate 
buffer, pH 6.4 followed by gradient elution with 0-0.3 M PBS, pH 6.4. Homogeneity 
of the protein was demonstrated by SDS-polyacrylamide gel electrophoresis and 
immunoelectrophoresis. A solution at concentration of 1 mg/ml TCS was prepared 
by dissolving in phosphate buffer saline (PBS), pH 7.2. Protein concentration was 
determined spectrophotometrically using O.D. 280 nm. • 
The polyclonal antibodies against TCS were generated as described by Shaw 
et al (76). Antibodies were raised in 3-month-old (2.5 kg) albino rabbits using 
denatured TCS. Crystalline trichosanthin (100 /xg m 0.25ml normal saline containing 
0.5 % sodium dodecyl sulphate) was denatured by heat treatment at 80。C for 10 min. 
16 
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It was then diluted to a final concentration of 200 y.glm\, and emulsified with equal 
volume of complete Freund's adjuvant. The rabbits first received intradermal injection 
of 1 ml emulsion at a number of sites on the back. Afterwards, each rabbit received 
a total of five booster injections, containing the same quantity of antigen but 
emulsified with incomplete Freund's adjuvant at 3-week interval. During this time, 
the activities of the antiserum were monitored by immunoblotting (77) using the 
ProtoBlofM system (Promega, WI, U.S.A.). Two weeks after the last injection, the 
ft 
rabbit with the highest antibody titre was completely bled and the antiserum collected 
and stored at -20°C. 
2. Preparation of iodinated Trichosanthin 
Trichosanthin was iodinated by using the chloramine-T method. Chloramine-T 
method (78) and metabisulphite solution were freshly prepared. For the reaction 
mixture, 500 /xCi N a ^ l (in 5 /d 0.5 M phosphate buffer, pH 7.5), 10 fxg chloramine-
T (in 10 yX PBS, pH 7.6) were added to 5 ng TCS (in 10 fil PBS, pH 7.6). The 
reaction mixture was agitated for 10 sec and the reaction stopped by the addition of 
50 fxg metabisulphite (in 100 /d PBS, pH 7.6). The unreacted iodide was separated 
from the labelled antigen by gel filtration chromatography on a Sephadex G-75 
column (1 X 14 cm). Non-specific sites on the column were saturated by rinsing it 
with 1 ml 2% bovine serum albumin (BSA) followed by 30 ml PBS (pH 7.6). The 
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iodination mixture was eluted with PBS (pH 7.6)，and 1.5 ml-fractions were collected 
in test tubes containing 0.2 ml 1 % BSA and 0.1 % sodium azide in the elution buffer. 
The peak tubes that contained the highest count of i巧-TCS were used and stored at 
40c. 
3. Radioimmunoassay procedure 
Radioimmunoassay was performed by using a d oub l e - a n t i b o d y polyethylene 
glycol (PEG) method under equilibrium conditions. The assay buffer used contained 
0.01 M PBS with 1% BSA and 0.1% sodium azide, in which standards, antisera, 
normal rabbit serum and labelled antigen were diluted. 
A typical reaction mixture contained 100 /xl each of ^^I-TCS (about 20,000 
cpm), 2% normal rabbit serum, standard (5-1000 ng/ml) or sample, antisera (final 
concentration 1:25,000) and assay buffer. Non-specific binding was accessed by 
substitutizing the aliquots ofantisera and standard with same volumes of assay buffer. 
The final volume was 500 /xl per tube and all tubes were made in duplicates. The 
assay tubes were then incubated overnight at room temperature. 
In order to separate the free antigen from antibody-antigen complex, the latter 
was precipitated by adding 200 - of goat anti-rabbit r-globulin (1:40 in assay buffer 
18 
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with 10% PEG 6000). After incubation for 15 min at it was then centrifuged 
for 4 min at 9000 r.p.m. at The supernatant was removed, washed once with 
ice-cold PBS. The radioactivity in the pellet was determined with a Kontron gamma 
counting system. Results were automatically calculated using a computer programme, 
based on log-logit transformation. 
4. Coupling of Trichosanthin to dextran T40 
The dialdehyde method described by Tarn et al (66) was essentially followed 
to prepare the dextran-trichosanthin (DX-TCS) conjugate. In this method, 10 ml of 
dextran T40 (100 mg/ml) with an average molecular weight of 40 kDa was first 
oxidized by 1 ml of sodium periodate (120 mg/ml) and then left overnight in the dark 
at 4。C. Afterwards, freshly prepared sodium bisulphite (300 mg/ml) was added drop 
by drop until the mixture turned brown and then colourless again. The activated 
dextran was then dialysed against distilled water. 
Coupling of TCS to dextran was done at different TCS/dextran molar ratios 
of 1:100, 1:50，1:25, 1:10, 1:5 and 1:2.5, respectively. The pH of the reaction 
mixture was adjusted to 9.5 by adding 0.3 M sodium carbonate and the mixture was 
left overnight at After the reaction, successful coupling was confirmed by gel 
exclusion chromatography on a Sephadex G-200 column (1.8 X 55 cm). Samples 
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were eluted with PBS, pH 7.6. The void volume of the column was determined using 
blue dextran (2 X 10^  daltons). Four-millilitre fractions were collected and the TCS 
concentration of each fraction determined by radioimmunoassay as described 
previously. 
5. Plasma protein binding of Trichosanthin 
Plasma protein binding to TCS was evaluated by using Centricon-30 
microconcentrator. Same quantity of TCS was either incubated with PBS or rat 
plasma at 37°C for 15 min. Then the mixtures filtered through a membrane with 
molecular cut off of 30,000 (Centricon-30). The concentration of TCS in the 
ultrafiltrate was determined by radioimmunoassay described above. 
I 
： -
I 6. Pharmacokinetic study 
] • 
The pharmacokinetics of a single i.v. bolus injection of TCS or DX-TCS were 
studied in male Sprague-Dawley rats weighing between 350 and 400 g. After an 
overnight fast, the rats were anesthetized by 4.5% sodium pentobarbital (60 mg/kg 
i.p.). The jugular vein was cannulated for drug injection. The carotid artery was 
cannulated for blood sampling and blood pressure measurement. The trachea was also 





in it to collect urine. The penis was also ligated to prevent extravasation of urine. The 
temperature of the rats was maintained by a lamp shining directly on the rat. In some 
rats, the kidney was rendered non-functional by Hgating the renal arteries. After the 
surgical procedures, a single dose of txitiated inulin (6 /xCi) was given to the rats 
through the jugular vein. Rats were divided into 3 groups. Group 1 were normal rats 
injected with TCS (0.75 mg/kg). Group 2 were renal artery-ligated rats injected with 
TCS (0.75 mg/kg). Group 3 were normal rats injected with DX-TCS (0.75 mg/kg). 
Plasma samples (0.3 ml) were taken at 2，5，15，25, 35，45，135 and 180 min after 
injection. Urine samples were collected at 45，90，135, 180 min after drug 
administration. Renal function was assessed by examining the plasma tritiated inulin 
excreted in urine. 
is 
！ In determining plasma and urine tritiated inulin, aliquot of 50 jxl of samples 
1 
I were added to 10 ml of the scintillation cocktail which contained 2,5-diphenyloxazole 
'f -
(PPO), l ,4-bis-2-(5-phenyloxazolyl)benzene (POPOP) and Triton X-100 in toluene. 
The vials were then counted for a maximum of 10 min by using Beckman LS 7000 
liquid scintiUation system. Plasma and urine concentrations of TCS or DX-TCS were 
determined by the radioimmunoassay as described earlier. 
j 
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7. Reabsorption of Trichosanthin 
Two sets of experiment were performed to illustrate that TCS was reabsorbed 
by renal tubular cells. First, the relationship between various doses of TCS injections 
i • 
and its urinary excretion was examined. Rats were prepared according to the previous 
I 
I surgical procedures. Different doses of TCS (0.375 mg/kg, 0.75 mg/kg, 1.5 mg/kg, 
I _ .-
3.0 mg/kg, 12mg/kg) were injected. The plasma concentration of TCS at 45，90 and 
135 min and the percentage of injected TCS recovered in urine during this time 
interval were determined. 
i 
In another set of experiment, the competitive nature of TCS with other protein 
for renal reabsorption was studied. In this experiment, either normal saline solution, 
5 g / i ( 77.5 ^M) of stroma-free haemoglobin solution (66) or 1.13 g/1 (77.5 ixU) 
lysozyme solution was infused (3.4 ml/hr) into similarly prepared rats. After 90 
minutes of infusion, 0.375 mg/kg TCS was injected intravenously and the urinary 
TCS excretion was measured at 45 minutes interval by the radioimmunoassay 
described above. The glomerular filtration rate of the rats was estimated by tritiated 
inulin clearance. 
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8. Biological activities of DX-TCS conjugate 
I. in vivo bioassay - Mid term abortifacient activity 
Pregnant mice were prepared by the University Animal House. During the 
preparation, mature female mice were caged with fertile males. The presence of 
copulation plug in the following morning is designated day 1 of pregnancy. Assay 
was done by injecting various doses of TCS and DX-TCS intraperitoneally into the 
mice on day 12 of pregnancy. The mice were autopsied on day 14 of pregnancy. The 
total number of uterine implantation sites were recorded. The no. of live fetuses, dead 
fetuses whose hearts had stopped pulsating, and resorbing fetuses were recorded. 
Mice were considered aborted when the no. of dead fetuses exceeded 50% of the total 
I . I [ 
i r 
implantation sites, 
n . in vitro bioassays 
A. Mitogen-induced lymphocyte transformation 
Three to four inbred C57 BL/6N mice (6-8 weeks old) were killed with 
cervical dislocation. Their spleens were removed aseptically, minced with a pair of 
scissors and pressed against a sterile 60 mesh stainless steel screen with the plunger 
of a 5 ml plastic syringe. Large cell clumps which passed through the screen mesh 
were removed by centrifuging at 500 g for 10 sec. The cells were then pelleted and 
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resuspended in Tris-buffered isotonic NH4CI solution for 2-5 min to lyse the red 
blood cells. The cell suspension was then centrifuged at 500 g, 4。C for 5 min and 
washed two times with RPMI medium. The viability of the final cell suspension was 
j determined by the trypan blue dye exclusion method (80). Spleen cells with the 
i 





I - _ . 
I ； Spleen cells were cultured in flat-bottomed 96-well microliter plates at 5X10^ 
i. . -. . • 
I 
cells/well in a final volume of 0.2 ml RPMI complete medium (RPMI medium 
i , 
supplemented with 10% foetal calf serum and containing 100 units/ml of penicillin 
？ 
! 
G, 100 /xg/ml of streptomycin sulfate and 3 ^g/ml of fungizone). Mitogens at 
predetermined optimum concentrations were then added to cultures containing various 
concentrations of TCS, DX-TCS and dextran. Mitogens used include concanavalin A 
(Con A, 3 /ig/ml), phytohaemagglutinin A (PHA, 10 ^g/ml) and lipopolysaccharide 
(LPS, 30 jLtg/ml). The cultures were kept for 48 hr at 37。C in a humidified incubator 
containing 5% CO2. After the culture period, each well was pulsed with 0.5 fiCi of 
the labelled DNA precursor, [methyPH]thymidine (^H-dTR) for 6 hr. The 
radioactivity incorporated was harvested by a PHD cell harvester (Cambridge Tech.) 
on a glass fiber filter. The filter was suspended in scintillation cocktail and counted 
by using Beckman LS 7000 liquid scintillation system. 
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In a separate experiment, lymphotoxicity was checked by incubating the mouse 
lymphocytes with a high concentration (50 /zg/ml) of TCS, DX-TCS or dextran for 
48 hr. The % viability was assessed by using the trypan blue dye exclusion method 
(80). After the incubation period, 50 fil of cells was pipetted out and mixed with 10 
/J 1 % trypan blue dye. Five minutes later, cells which were stained blue as observed 
I under the microscope were regarded as dead cells. The degree of cytotoxicity was 
then evaluated by comparing with the control in the absence of drugs. 
• . 
B. Anti-tumor activity 
I . 
The in vitro anti-tumor activity of TCS and DX-TCS was assessed on 2 
different cell lines, PU5-1.8 and H35 obtained from ATCC. PU5-L8 is a 
macrophage-Hke cell line derived form BALB/c mice while H35 is a rat hepatoma 
cell line. PUS cells and H35 cells were maintained in 25 cm^ culture flask in complete 
RPMI medium and complete minimal essential' medium (MEM) respectively. They 
were subcultured every 2-3 days after the ceUs almost formed confluent monolayer. 
During the subculture process, the cells that attach to the culture flask were 
trypsinized (0.25% trypsin containing 0.01% EDTA) for 2-5 min at 37°C. 
Trypsinization was stopped by addition of complete medium to the trypsinized cell 
suspension. The cells were washed once with complete medium. About 10^  viable 
cells were then resuspended in complete medium into the culture flask. 
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In the anti-tumour assay, different concentrations of TCS, DX-TCS or dextran 
were co-cultured with 5Xlt f tumour cells at their logarithmic phase of growth in 0.2 
ml complete medium in the wells of a flat-bottomed 96-well microtitre plate. After 
48 hr culture, the growth inhibitory activity of TCS, DX-TCS or dextran on tumour 
cells was measured as described for the ^H-TdR incorporation assay. Since both are 
i 1 
I of adherent cells, 50 fA of 0.1 M NaOH was added to each well to detach the 
i 
i 
adherent cells prior to the normal cell harvesting procedure. 
The direct cytotoxic effect of TCS, DX-TCS or dextran on the cultured 
tumour cells were also studied. 5-10X10^ tumour cells were incubated with a high 
concentration (100 /xg/ml) of TCS, DX-TCS or dextran for 48 hr, and cell viability 
was assessed by using the trypan blue dye exclusion method. Cells which were 
stained blue as observed under the microscope were regarded as dead cells. 
Cytotoxicity, as judged by cell killing can then be evaluated. 
9. Immunological activities of DX-TCS conjugates 
I. Binding activity of DX-TCS conjugate to TCS antibodies 
The binding activities of TCS and DX-TCS to TCS antibodies were compared 
in this study. Competitive binding studies were performed as describe above (p. 18) 
26 
to examine whether DX-TCS still retains its specific binding capacity to TCS 
antibodies. Binding study of DX-TCS with the dextran moiety digested by incubating 
the complex with dextranase at pH 7.6 and 36®C for 20 hr was done. The effect of 
dextran and/or dextranase on the TCS competitive binding curve were also studied 
by adding these substances to the assay. 
I . . . - " • 
II. Production of IgG and IgE antibody to TCS and DX-TCS in mice 
I ‘ 
•1 
j C57 BL/6N inbred mice (6-8 weeks old) were used for the experiments. Mice 
！ j 
I in groups of five were immunized subcutaneously at the back with TCS (10 fig), DX-
[ 
I TCS (10 /ig) and dextran in complete Freund's adjuvant on day 0. The booster 
injection was given on day 21 using the same antigens but with Freund's incomplete 
adjuvant. The bleeding of the primed mice was carried out 14 days after the booster 
) ‘ • 
I injection. Blood was collected through retro-bulbar puncture under light ether 





Another experiment with same immunization protocol was done for 
comparison in which adjuvant was not used. Parallel groups of the same strain of 
mice were immunized with the same antigen in vegatable oil instead. Moreover, 
hyperimmune mouse sera against TCS which has been characterized by 
radioimmunoassay was obtained from Dr. C. C. Wong as positive control. 
27 
Specific IgG and IgE antibodies against TCS, DX-TCS and dextran were 
detected by conventional enzyme-linked immunosorbant assay (ELISA). ELISA plates 
(Immunoplate, Maxisorp, Nunc) were coated overnight at 4。C with 100 fxl of antigen 
(5 pg/ml TCS, DX-TCS or 100 fig/ml dextran) in 0.05 M sodium carbonate-
bicarbonate buffer (pH 9.6 with 0.1% sodium azide). On the following day the plates 
I 
I 
[ were washed three times with washing buffer (PBS, pH 7.2 with 0.05% v/v Tween-
20) and then blocked for 1 hr at 37°C with 200 jul/well blocking solution (washing 
buffer with 1 % BSA). After blocking the plates were again washed, then blotted dry. 
1 
I Positive control sample, antisera (diluted with washing buffer with 0.5% BSA) were 
I added, in triplicate, to the ELISA plate at 100 jul/well. The plates were incubated for 
1 hr at 37°C. The plates were then washed 3 times, followed by the addition of 100 
jxl detecting antibody (sheep anti-mouse IgG-horseradish peroxidase conjugate or 
sheep anti-mouse IgE) and incubated for 1 hr at 37°C. After this incubation period, 
the plates were washed and 100 /xl of enzyme substrate was added to each well and 
the plates were protected from light. For those plates of detecting IgE, another 1 hr 
incubation period with a antibody, donkey anti-sheep IgG-horseradish peroxidase 
conjugate was needed before adding the substrate solution. The substrate solution was 
o-phenylenediamine dihydrochloride (OPD). OPD tablets (4 mg/tablet) were dissolved 
in substrate buffer (0.2 M phosphate-citrate buffer, pH 5.0) containing 0.04% HjOj. 
This solution was always prepared and used within 60 min and held at room 
temperature in dark. After 30 min, the reaction was stopped with the addition of 50 
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Chapter 3: Development of Radioimmunoassay 
In order to study the pharmacokinetic, biological and immunological actions 
of TCS and DX-TCS, a prerequisite is to develop a method capable of detecting TCS 
both specifically and quantitatively. Such method should be able to measure TCS in 
I 
range of nanomole (la^ mole) or even picomole (lO'^^ mole) in biological fluids. As 
a result, the advantages of radioimmunoassay (RIA), including its extreme sensitivity, 
simplicity and specificity, make this the method of choice for the measurement of 
TCS• There are generally three basic steps in performing a radioimmunoassay. They 
are (1) production of antiserum to the compound to be measured, (2) preparation of 
radioactively labelled form of the compound and (3) competitive binding assay 
between the labelled and unlabelled antigen to the antibodies. Since protein is usually 
； . 
I immunogenic in its own right, production of antiserum is done by injecting the pure 
j . 
compound with adjuvant into a suitable animal like a rabbit. This is then followed by 
I several booster injections. The dilution of antiserum to be used for a particular 
i • 
I • 1 , . 
radioimmunoassay is determined by incubating a fixed concentration of labelled tracer 
with increasing dilutions of antiserum. 
Afterwards, a suitable radioisotope should be chosen and gamma-emitting 
radionuclides is usually used in the preparation of labelled tracers for 
radioimmunoassay.⑵Iodine is used for the preparation of labelled protein tracers 
30 
because it has a relatively long half-life of 60 days. It is also convenient to use as it 
can be readily substituted into tyrosine residues of the protein by the chloramine-T 
method (78). The chloramine-T method is one of the widely used method of 
iodination. Chloramine-T is the sodium salt of the N-monochloro derivative of p-
toluene sulphonamide and is a mild oxidizing agent in aqueous solution. The reactions 
！ thus involve the oxidation of Na⑵-I in the presence of a protein containing a tyrosine 
！ i 
residue, with the subsequent incorporation of the radioiodine into the tyrosine. The 
excess chloramine-T is reduced by the addition of sodium metabisulphite, and free 
iodine is reduced to iodide. After the preparation of labelled antigen, competitive 
binding radioimmunoassay can then be performed. 
Method 
The full experimental details of production of antiserum, iodination of TCS 
and the radioimmunoassay procedure were described in methodology (Chapter 2). 
Since the assay developed will be used to detect TCS in plasma and urine, the effects 
of adding normal rat plasma and urine in the standard assay tubes was done. Its aim 
is to examine the specificity of the assay and to see if there is any constituent in the 
plasma or urine that might interfere with the antigen-antibody reaction. 
31 
"V 
To determine the inherent variability within a single assay, ten replicate tubes 
containing known quantities of TCS (100 ng/ml) were measured in a single assay and 
the intra-assay variance was calculated. Moreover, the inherent variability between 
assays was also determined using aliquots of TCS solution (100 ng/ml) stored in -
20°C. Two such aliquots were then included in five separate assays and the inter-
j 
j assay variance was determined on this basis. Sensitivity of the assay was determined 
by taking the lowest TCS concentration which will give a percentage binding that can 





Statistical analysis between the standard curves done in buffer, plasma and 
urine was performed by using 10 randomly picked standard curves of each kind. 
.Their slopes and Y-intercepts were compared by one way analysis of variance 
followed by Scheffe's multiple comparison test using the SPSS-PC + computer 
program. The curves were considered identical if their slopes and intercepts did not 
different significantly (p<0.05). • 
Results 
Fig. 3.1 shows the gel-filtration profile of radioiodinated TCS. The '^I-TCS 
32 
which had a higher molecular weight than free ^i，was eluted out first. The tubes 
• that contained the highest count were used in the radioimmunoassay. The % of iodine 
incorporated was calculated as about 51% and the specific activity of TCS was over 
50 fiCi/fig (1300 Ci/mmol). 
i ；Pig. 3.2 shows the typical standard curves obtained from the 
radioimmunoassay. Calibration curves were constructed using the coordinates B/BO 
X 100% versus the logarithm of the unlabelled antigen concentration. Under the 
conditions stated above, the specific binding (BO) was about 33% while the non-
specific binding was less than 3%. When comparing the three curves, addition of 
normal rat plasma makes'no statistical difference while addition of rat urine shifted 
the curve to the right. The intra-assay and inter-assay variance were 7.5% and 9.7% 
respectively. The sensitivity of the assay was found to be 2.5 ng/ml in plasma and 5.0 
ng/ml in urine. 
33 
# 
6 /〇 \ 
^ R V O O I J I 4 - E -
0 5 10 15 20 25 
Fraction No. 
Fig. 3.1 Chromatogram on the separation of radioiodinated TCS (⑵I-TCS) 
from free ^iodine (⑵I). 
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The chloramine-T reaction during iodination seems satisfactory since high 
incorporation of radioiodine into protein was obtained (Fig.3.1). In fact, this method 
is technically simple and rapid to perform and is usually used to iodinate a protein in 
the first time. It is then used routinely to iodinate TCS for use as tracer in the 
subsequent radioimmunoassays. 
A sensitive radioimmunoassay was successfully developed to detect TCS both 
specifically and quantitatively. The assay conditions were also optimum since we 
could obtain about 30% specific binding (BO) which would consequently yield a better 
sensitivity of the assay. Indeed, it is rather sensitive since it can detect TCS in the 
nanogram range. Moreover, the non-specific binding was insignificant (only 3%). 
Addition of 10% polyethylene glycol increased the size of the precipitate through the 
decrease in solubility of immune complexes without affecting the non-specific 
binding. The assay also appears to be reasonably consistent in the measurement of 
TCS according to the calculated coefficients of variance. 
The assay performed in rat plasma was not different from those in standard 
assay buffer showing minimal interference by plasma components in the 
measurement. However, there was a right shift of the standard curve after addition 
36 
of urine in the assay. This may be due to some inhibitory substances present in the 
urine that affect the antibody-antigen reaction. Girard et al found that non-specific 
factors in urine, measuring as apparent growth hormone, were detected when the 
radioimmunoassay for plasma growth hormone was applied to urine. The factors was 
identified as salt (NaCl) and urea presented in the urine (97). Srivastava et al also 
proved this inhibitory effect by showing the shifting of standard curve to the right 
after addition of urea or NaCl (98). This phenomena is termed as "non-specific non-
specificity" which refers to the interference by materials which do not directly react 
with the antibody, but can nevertheless affect the primary antibody-antigen reaction. 
For this reason, we should eliminate the "matrix effects" of urine when using RIA 
to measure samples. The best approach is to ensure the composition of the standards 
mimics that of the unknown samples. This can be done by adding normal rat urine 
I -
to the standard tubes so that a urine standard curve is obtained for the measurement 
of TCS in urine. 
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Chapter 4: Coupling of TCS to Dextran T40 
The molecular weight of TCS is only 26 kDa and is therefore small enough 
to undergo glomerular filtration. This would lead to a short half-life of this protein 
in the body due to rapid renal clearance (50,51). As a foreign protein, it is also 
immunogenic in nature as it would cause anaphylactic response in some patients 
receiving the drug (93,94). These problems may be overcome by modification of the 
protein. Thus, an appealing solution is to couple TCS covalently to another 
macromolecule like dextran T40 (average molecular weight of 40 kDa). There are 
two potential consequences after coupling. First, it increases the molecular weight of 
I TCS from 26 kDa to 66 kDa. If glomerular filtration is an important determinant of 
TCS elimination, filtration of the larger TCS through the kidneys will be greatly 
impaired and its serum half-life can be prolonged. Secondly, the immunogenicity of 
TCS may be decreased when complexed with dextran. The binding of the 
polysaccharide sterically protects the foreign protein from recognition by the immune 
system through the blocking of the epitopes on the molecule. 
Dialdehyde method was used for the coupling of TCS to dextran. This method 
had been adopted by Tarn et al (66) for conjugation of haemoglobin to dextran. In 
fact, it was first developed by Hemming et al (81) for coupling trypsin to the 
insoluble cellulose. In this method, the adjacent hydroxyl groups of dextran are first 
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•i. 
oxidized by sodium periodate and the ring structure of dextran is opened to form a 
dialdehyde function which in turn reacted with the amino group of TCS through the 
carbinolamine linkage (Fig4.1). Successful coupling was then confirmed by 
biochemical methods such as gel-filtration chromatography or SDS polyacrylamide 
gel electrophoresis. 
i 
I - •… 
. - - . 
Method 
- - ‘ 
The method of coupling used by Tarn (66) was generally followed and 
described in methodology (Chapter 2). During coupling, various TCS to dextran 
molar ratios (1:2.5, 1:5, 1:10, 1:25, 1:50, 1:100) were done. The purpose is to 






I After the reaction, the efficiency of coupling was examined. If complete 
i - -
coupling occurred, there was no need to separate the free TCS from the conjugated 
TCS. Apart from gel-filtration chromatography as described previously, successful 
coupling was also confirmed by using Centricon-30 microconcentrator. The DX-TCS 
solution prepared was loaded to the concentrator's sample reservoir and the device 
was centrifuged by a fixed angle centrifuge. Centrifugal force drives solvents and the 
low molecular weight solutes through the membrane with a molecular weight cut-off 
of 30 kDa, while macromolecules above the membrane cut-off are retained in the 
39 
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sample reservoir. The contents that were filtered through the membrane were then 
analyzed by radioimmunoassay. Trichosanthin with a molecular weight below 30,000 
would pass through the membrane and appear in the filtrate but not DX-TCS. 
The approximate molecular weight of the conjugate was also determined by 
SDS polyacrylamide gel electrophoresis by comparing with SDS molecular weight 
markers. The polyacrylamide gel was stained using silver staining kit (Sigma) with 
the detection limit between 10,to 50 nanogram of protein. Stability of the conjugate 
after storage for different period of time (up to 6 months) at 4°C was also examined 
by the above method. In addition, the UV absorption spectrum before and after 
coupling was examined using the scanning spectrophotometer with the range from 
O.D. 190 to O.D. 300 nm. 
1 
I . . - . . -
i --. -
Result 
Fig. 4.2 shows the elution profile of different reaction mixtures at various 
dextran and TCS molar ratios on a Sephadex G-200 column. TCS was eluted out as 
a single peak at Fraction No. 23-24 (Fig. 4.2A). After the coupling reaction, TCS 
activity was eluted out at a much faster rate on the Sephadex column. This indicated 
successful coupling since the DX-TCS complex now had a larger molecular size and 
moved faster during gel filtration chromatography. Moreover, at high ratio of TCS 
40 
to dextran (over 1:25), coupling was essentially complete and there was clear 
separation between TCS and DX-TCS (Fig. 4.2B). In addition, when TCS to dextran 
ratio was less than 1:25, coupling became incomplete as indicated by the presence of 
unreacted TCS in the position of TCS peak (Fig. 4.2A). Preparation of DX-TCS for 
all subsequent experiments was therefore done at TCS to dextran molar ratio of 1:25 
which is the lowest molar ratio producing complete coupling. 
Besides, ultrafiltration study through a Centricon-30 (molecular cut off 30,000) 
microconcentrator showed that TCS was able to pass through the membrane while 
DX-TCS (1:25) could not since no detectable TCS activity was found in the filtrate. 
I This further supported that coupling of TCS to dextran was complete. 
1 . 
j Similar pattern was obtained in SDS polyacrylamide gel electrophoresis, free 
I • 
TCS was detected when the ratio of TCS and dextran was less than 1:25 while 
complete coupling was seen when the ratio was above 1:25. There was a continuous 
distribution of the molecular size of DX-TCS (Fig. 4.3). Molecular weight was over 
66 kDa as determined from the molecular weight markers. Indeed, similar pattern was 
observed in gel filtration chromatograph as DX-TCS was eluted out near the void 
volume. The conjugate seemed to be very stable. No observable change occurred 
when stored at 4。C for up to six months as seen from the result of polyacrylamide 
gel electrophoresis. On the other hand, coupling produced minimal change to the UV 
41 
absorption spectrum of the protein (Fig. 4.4) especially at O.D. 280 nm which was 
used for the determination of protein concentration. 
I •…. 
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Fig. 4.2 Elution profile of different reaction mixtures at different dextran and 
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Fig. 4.3 SDS PAGE electrophoresis of TCS and DX-TCS. Lane 1: molecular 
mass standards; Lane 2: TCS; Lane 3: DX-TCS with TCS to dextran molar 
ratio below 1:25; Lane 4-6: DX-TCS stored at 4°C for 1 month, 3 months 
and 6 months respectively. 
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Fig. 4.4 Scanning spectra of TCS and DX-TCS at the UV region. 
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Discussion 
Dialdehyde method is one of the most common procedure developed for 
coupling proteins to dextran. I t is rapid, simple, straightforward and safe. Indeed, 
many examples of dextran periodate activation for the preparation of protein 
conjugates are described in the literature (61,62,71,72). During conjugation, oxidation 
of the hydroxyls of dextran with sodium periodate solutions leads to aldehyde 
functionalities that easily react with amine derivatives (82) • I t should be reminded that 
j the activated dextran or polyaldehyde dextran has to be used in a short period of time 
I (about one week) for the conjugation reaction. The addition of sodium bisulphite 





! Different molar ratio of dextran to TCS was used in the coupling reaction. Its 
I aim is to find an optimum reaction condition so that the yield of synthesis of the 
i . 
complex could approach completion. As a result, separation of DX-TCS from residual 
TCS could be avoided. Complete coupling was seen when the molar ratio of TCS to 
dextran was 1:25 due to the abundance of activated dextran to bind the TCS 
molecule. Hence, it was unnecessary to use a higher molar excess of dextran over 
TCS to achieve completion. However, a molar ratio below 1:25 was insufficient to 
drive the reaction towards completion and free TCS remained. 
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The oxidized dextrans are multifunctional with many reactive aldehyde groups 
per molecule and the protein also has many reactive amino groups. Therefore, in 
principle, the coupling between these two types of molecules could yield a complex 
mixture of products differing in their molecular sizes and compositions and in their 
sites of coupling. In fact, this was seen in the DX-TCS preparation which showed a 
spectrum of molecular sizes of the conjugates ranging from over 66 kDa to near 100 
kDa. Molecular weight of 66 kDa was obtained when one molecule of TCS linked to 
one molecule of dextran (DXi-TCSi). However, for higher molecular weight 
conjugate, there may be a chance of getting 2 TCS molecule attached to 1 dextran 
molecule (DXrTCSj) or 1 TCS molecule attached to 2 dextran molecule (DX2-TCS). 
•1 
i Further increasing the size of conjugate was limited by the steric packing of dextran 
i 
i and TCS molecule. The conjugate was also very stable upon storage at 4。C and no 
t -
j free TCS was detected. Moreover, it seemed that the coupling reaction did not alter 
i ‘ 
much the spectral property of the protein. 
In summary, a covalent dextran-trichosanthin complex was successfully 
synthesized by the dialdehyde method. The reaction is reproducible with the 
production of a stable conjugate. 
！ . -
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Chapter 5: Pharmacokinetic Study 
After the development of a sensitive radioimmunoassay for the detection of 
TCS in plasma and urine and the successful coupling of TCS to dextran T40, it comes 
to the pharmacokinetic study of TCS and its conjugate using rat as the animal model. 
The aim is to evaluate the role of kidney in the elimination of the drug and to see 
whether coupling will increase the persistence of TCS in the circulation. If renal _ 二 
excretion is the major route of TCS elimination, coupling of TCS to dextran would 
probably prolong its half-life in the circulation by preventing it from entering the 
kidney. One of the examples is the coupling of haemoglobin to dextran which 
subsequently lead to a prolonged circulatory half-life (66). The pharmacokinetic 
behaviour of DX-TCS was therefore compared with that of parent compound to see 
•j 
； how coupling affected the elimination of TCS. After the experiments, two 
I • - - -…— 
i approaches, namely (i) compartmental analysis and (ii) non-compartmental analysis 
j 
j were employed to characterize the pharmacokinetics of the drug and its conjugate 
- , . . 
(83). 
Compartmental analysis is the most commonly employed method. The body 
is considered to be consist of several compartments (compartment 1，compartment 2, 
etc.). In a pharmacokinetic sense, a compartment refers to those organs and tissues 
for which the rates of uptake and subsequently clearance of drug are similar, 
j ‘ 
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Sometimes these compartments have no physiologic or anatomic reality. It also 
assumes that the rate of transfer between compartments and the rate of drug 
elimination from compartments follow first-order or linear kinetics. In general, 
compartment 1 is the central vascular compartment whereas compartment 2 is a rapid 
accessible compartment (e.g kidney, liver), and compartment 3 refers to the more 
"deep" peripheral or slow accessible compartment like skin, bone, and muscle.-
During analysis, the goal is to find out whether the plasma concentration-time curves 
are best fitted in terms of a triexponential function (3-compartment model) or a 
biexponential function (2-compartment model). Their respective equations are shown 
below: 
Triexponential equation: Cp(t) = + B.批 + Ce"^ 
1 




j In these equations, Cp(t) is the plasma concentrations of the drug at any time (t) after 
I i.v. drug administration. A, B, C are the corresponding zero-time intercept, and a, 
\ 
I B, r are the apparent first order disposition constants. 
I 
Apart from the above method, the data were also analyzed by using the non-
compartmental analysis. In this method, it does not require the assumption of specific 
compartmentalization and therefore can apply to virtually any compartmental model 
provide that we can assume linear pharmacokinetics. Both compartmental analysis and 
non-compartmental analysis will be used in data analysis and to see whether there are 
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differences between the two. 
Method 
The experimental protocol of the pharmacokinetic study was described in 
methodology. The pharmacokinetic study of TCS was done in normal rats (group 1) 
and renal artery-ligated rats (group 2). The pharmacokinetic behaviour of DX-TCS 
was examined in normal rats (group 3). The reason for doing group 2 rats is to 
investigate the role of kidney in eliminating TCS. Renal function of group 2 rats were 
impaired by bilateral ligation of the renal arteries. As a consequence, we can 
investigate the disposition and elimination of TCS in the absence of kidney. Tritiated 
] 
inulin were administrated at the beginning of the experiment so as to access renal 
function. Since kidney is the only organ that removes inulin, theoretically, plasma 
i - _ . 
inulin concentration should decrease with time in normal rats with normal renal 
function. In contrast, a constant plasma inulin concentration is expected in renal 
arteries ligated rats. 
The plasma and urine concentrations of TCS or DX-TCS were determined by 
the radioimmunoassay method as described above. Determination of plasma DX-TCS 
was done under disequilibrium condition using DX-TCS as standards to increase the 
sensitivity of the assay. Thus, the unlabelled standard DX-TCS have an advantage of 
51 
binding with the TCS antibodies first at 4®C overnight. Afterwards, labelled antigen 
was added to react with the TCS antibodies for 24hrat4°C which was then followed 
by normal radioimmunoassay procedure. 
In a separate experiment, the plasma protein binding to TCS was evaluated as 
mentioned in the methodology (Chapter 2). In principle, any molecule with a 
molecular weight below 50,000 and not bound to any plasma protein are filterable 
through the kidney. Therefore, in addition to the pharmacokinetic study, it is 
important to demonstrate the plasma protein binding of TCS is minimal in order to 







Pharmacokinetic parameters were calculated by the BITRI computer program 
i 
using method of residuals for compartmental analysis (83) and the PKCALC computer 
program for non-compartmental analysis. Statistical analysis of group differences 
were performed by Tamhane's multiple comparison with unequal variances (99) at 
significant level of p < 0.05. 
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Result 
After a single bolus injection of tritiated inulin, a constant plasma inulin 
concentration was observed in the ligated rats (group 2) demonstrating that there was 
a complete loss of renal function in this group of rats (Fig. 5.1). On the other hand, 
the plasma concentration of inulin in normal rats (group 1) decreased with time. As 
a consequence, the injected TCS in group 2 rats was now distributed and eliminated 
without the involvement of kidneys when compared with group 1 rats. Blood pressure 
was not changed after injection of TCS or DX-TCS into the rats. There was also 
swelling of the footpads of the rat receiving DX-TCS injection. 
•j 
Figure 5.2 shows the plasma concentration vs time in three groups of rats. 
j 
\ When TCS was injected into normal rats, the concentration of TCS declined rapidly 
I . 
I within 45 min and resulted in a 100 fold difference from time zero. In contrast, when 
5 
TCS was injected into ligated rats, the plasma concentration of TCS decreased in a 
I _ 圓 
！ much slower rate. Injection of DX-TCS resulted in a similar pattern as in the ligated 
rats. The plasma DX-TCS concentration was highest at any time during the 
experimental period comparing to the injection of same dose of TCS (in both normal 
and ligated rats). Some calculated pharmacokinetic parameters were summarized in 
Table 5.3 using non-compartmental analysis. Comparing with TCS injected into 
normal and ligated rats, DX-TCS injection resulted in having the longest mean 
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residence time (MRT) which represents the time for about 60% of the administered 
dose to be eliminated. Area under curve (AUG) was also found to be the highest 
which indicates a change in total clearance rate. In fact, this can be seen as the 
plasma clearance (Clp) was lowest for DX-TCS. A l l these parameters suggested that 
the modified form of TCS stayed much longer in the circulation. 
When using compartmental analysis, most of the pharmacokinetic parameters 
calculated (e.g. AUG, Clp, etc.) were similar to the non-compartmental analysis and 
followed the same trend (Table 5.4). In addition, the iVi^a), which is the half-life of 
the drug at the initial distribution phase, was longest in ligated rats. Moreover, TCS 
injection (group 1) was consistent with a three-compartment model while DX-TCS 
j injection (group 3) or TCS injection into ligated rats (group 2) were consistent with 
a two-compartment model. A l l pharmacokinetic parameters (Table 5.3 and 5.4) were 
significantly different between the three groups of rats (p<0.05). 
* 
Urinary excretion data showed that only 0.38 土 0.05% of the administered 
TCS was recovered in urine within 180 min of experimental period. Nearly all the 
• urine TCS was recovered in the first 45 min interval (86 士 5%). No DX-TCS 
activity was detected in the rats with DX-TCS injection (group 3). 
In the plasma protein binding experiment, result demonstrated that plasma 
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protein binding to TCS was minimal. Incubation of TCS with plasma did not affect 
its ultrafiltration in the Centricon-30 microconcentrator. The filtrate concentration of 
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Fig. 5.1 Plasma inulin concentration in normal and ligated rats. Values are 
expressed as means 土 SEM (N=6). 
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Fig. 5.2 Plasma concentration time curves of 0.75 mg/kg TCS injection into 
normal (N=6) and ligated (N=8) rats, and DX-TCS injection (0.75 mg/kg) 
into normal rats (N=6). Values are expressed as menas 土 SEM. 
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、 
~ N o r m a l Ligated DX-TCS 
II (N=6) (N=8) (N=6) 
tV2(a) (min) 2.2 土 0.3 14.5 士 1.1 8.5 土 0.9 
V , (ml/kg) 506 士 40 142 士 14 46 土 1 
Vss (ml/kg) 75 ± 6 % 土 8 45 土 1 
AUCg Qig-min/ml) 81 土 16 1534 士 216 5228 土 684 




I Table 5.3 A summary of some pharmacokinetic parameters in normal rats injected 
i with TCS or DX-TCS and ligated rats injected with TCS using compartmental 
analysis. Values are expressed as means 士 SEM. A l l three groups are significantly 
different from each other (p< 0.05). Abbreviations: tViia), distribution half-life; V^, 
apparent distribution volume, V沾,steady state distribution volume; AUCq , area under 
curve; Clp, plasma clearance. 
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Normal Ligated DX-TCS 
(N=6) (N=6) 
Vz (ml/kg) 507 士 36 97 士 6 45 士 1 
V,, (ml/kg) - 127 + 9 84 土 4 45 士 1 
AUCg (Mg-min/ml) 59 士 6 1285 士 10乏 5095 士 1634 
Clp (mymin) 4.78 土 0.57 0.22 士 0.02 0.06 土 0.04 
MRT (min) 9 ± 1 | 145 土 16 308 土 41 
I 
1 Fig. 5.4 A summary of some pharmacokinetic parameters in normal rats injected with 
TCS or DX-TCS and ligated rats injected with TCS using non-compartmental 
analysis. Values are expressed as means 土 SEM. A l l three groups are significantly 
j different from each other (p < 0.05). Abbreviations: V „ apparent distribution volume, 
] V „ , steady state distribution volume; AUCJ，area under curve; Clp, plasma clearance; 
I MRT, mean residence time. i i 






It is expected that TCS can be filtered into the renal tubule due to its small 
molecular size and non-protein binding nature. The pharmacokinetic data obtained do 
suggest that this is the case. In the absence of renal function, the increase in area 
‘ 
under curve (AUG), mean residence time (MRT) and the reduction m plasma 
clearance (Clp) all suggested that kidney is the major eliminating organ for TCS. 
In compartmental analysis, the half-life of the initial distribution phase (Wia) 
was increased in ligated rats meaning that in this early distribution phase, plasma TCS 
declined at a much slower rate in the absence of renal function. On the other hand, 
I in normal rats, enormous amount of TCS was being distributed into the kidney 
！ ‘ 
followed by elimination during the initial phase. Rapid renal loss of TCS was also due 
to the high TCS concentration which in turn lead to an elevated filtered load. Another 
interesting finding in compartmental analysis is that DX-TCS injection was consistent 
with two-compartment model. Both V^ and were found to decrease. It seems that 
I ‘ i . 
a major distribution compartment of TCS is lost after coupling to dextran. This 
compartment is most likely the kidney since DX-TCS conjugate cannot enter it due 
to its large molecular size (over 66 kDa). This is analogous to the ligated rats which 
do not have a functional kidney. 
• 60 
Injection of DX-TCS produced the highest plasma concentration at any time 
during the entire experimental period as seen from Fig. 5.2 and the plasma DX-TCS 
concentration gradually decrease with time. This suggests the existing of extra-renal 
degradation of the conjugate since now the larger complex was not able to enter the 
kidney for elimination. The exact metabolic site was still unknown. Liver and the 
reticulo-endothelial system are the possible candidate since dextran conjugate has been 
reported to be taken up and degraded by these two sites (74). On the other hand, the 
pharmacokinetic parameters such as MRT, AUG, Clp all supported that DX-TCS 
stayed much longer than TCS in normal rats and even in ligated rats. On the basis of 
these finding, i f glomerular filtration of TCS is the only parameter that affects its 
elimination and distribution, one wi l l anticipate that the pharmacokinetic behaviour 
i i 
of DX-TCS in normal rats wi l l be the same as TCS in ligated rats. However, from 
j “ 
I 
both the concentration time curve and the pharmacokinetic parameters, DX-TCS 
I . 
I remained even longer in the plasma compartment than TCS in ligated rats. This 
I _ -
suggests that coupling of TCS to dextran not only reduces it rate of renal clearance, 
but also its rate of non-renal degradation. Probable, it may due to the fact that the 
covalent complex is more resistant to enzymatic degradation. 
‘ 
Rats are known to be sensitive to dextran (106). Indeed, this was demonstrated 
by the swelling of the footpads of the rat with DX-TCS injection. However, because 
there is no change in blood pressure and glomerular filtration rate (data shown in 
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Chapter 6)，the possibility that the sensitivity might affect the pharmacokinetic 
observations is therefore remote. 
When estimated from the mean residence time (about 10 min in normal rats), 
more than 60% of the administered TCS was removed within the experimental period 
of 180 min. As mentioned above, i f kidney is the major eliminating organ of TCS, 
one would anticipate that large amount of TCS be found in urine. However, the total 
amount of TCS that could be recovered from urine within the experimental period of 
180 min was only 0.38 土 0.05% which was much lower than expected. It then led 
to the speculation that after glomerular filtration, a large amount of TCS was 
somehow retained by kidney. It may be due to the precipitation of TCS in the renal 
tubules, being reabsorbed by tubular cells or non-specific binding by kidney tissues 
so that the amount of TCS cleared by the kidney cannot be fully recovered in urine. 
Amongst the possibilities, reabsorption of TCS by renal tubular cells is most likely 
as this is a common metabolic pathway of low molecular weight proteins (74,84,85). 
Further study to clarify this issue was done and discussed in the later chapter. 
In summary, kidney is major organ of elimination of TCS. Covalent coupling 
of TCS to dextran prolongs the survival of TCS in the circulation, mainly due to the 
increase in molecular size and thus the conjugate can escape from glomerular 
filtration. 
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Chapter 6: Renal tubular reabsorption of TCS 
In the previous chapter, it was shown that kidney is the major organ that 
eliminates TCS. Unfortunately, the amount of TCS lost could not be recovered in 
urine. Indeed, urine recovery of TCS was very small. A possible explanation is that 
the filtered TCS is reabsorbed by the renal tubular cells, degraded in the cells and the 
amino acids returned to general circulation. 
Kidney is an important site for the catabolism of low molecular weight 
proteins which have molecular weight less than 50,000 (e.g. lysozyme, insulin, 
ribonuclease,etc.) (74,84,85). After filtration of these proteins into the renal tubule, 
they are reabsorbed by receptor mediated endocytosis, and eventually catabolized in 
I 、 
j the proximal tubular cell. The entire process is rather non-specific for the nature of 
proteins. Trichosanthin has a molecular weight similar to these proteins and therefore 
it may be reabsorbed by this common endocytotic process. 
In order to support the hypothesis, two sets of experiment were performed. 
Firstly, rats would receive escalating doses of injected TCS. The purpose is to see 
whether the urinary recovery of TCS can be increased by saturating the reabsorptive 
capacity of the tubular cells after high dosage of injection. As described beforehand, 
filtered low molecular weight proteins are mostly reabsorbed by renal tubular cells 
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through a common endocytotic process. It was demonstrated that infusion of one 
protein can increase the excretion of another protein (86,87). Adopting this thought, 
in the second set of experiment, the competitive nature of TCS was examined. Hence, 
filterable proteins (haemoglobin and lysozyme) were infused into the animals to see 
i f they can compete with and increase the excretion of TCS. 
Method 
The general procedure for these two sets of experiment were described in 
Chapter 2. In the first experiment in which the dosage effect on urinary TCS recovery 
was studied, the five injection doses used were 0.375, 0.75, 1.5, 3 and 12 mg/kg. 
j 
After TCS injection, plasma samples were collected at 45, 90 and 135 min and urine 
I samples were collected at 45 min interval. Plasma and urine concentrations of TCS 





In the second set of experiment, the mechanism of TCS reabsorption was 
i 
I • 
examined. Rats were divided into 6 groups. After a loading dose of tritiated inulin, 
rats were then followed by continuous infusion of different fluids containing tritiated 
inulin at a rate of 3.4 ml/hr so that their respective glomerular filtration rate was 
monitored. Group 1, 2 and 3 rats were infused with normal saline solution (N=8), 
77.5 /xM stroma-free haemoglobin solution (N=9) and 77.5 /xM lysozyme solution 
64 
"t 
(N=9) respectively. Trichosanthin (0.375 mg/kg) was injected at 90 min after onset 
of infusion. Plasma and urine samples were taken at 45 min interval and the 
concentrations measured by radioimmunoassay. Moreover, group 4 rats (N=5) were 
continuously infused with normal saline solution but with DX-TCS (0.375 mg/kg) 
injection. Group 5 (N=7) and group 6 (N=6) rats were infused with normal saline 
and lysozyme solution only without any drug injection. Stroma-free haemoglobin 
solution was prepared according to a previously described method (66). Plasma 
haemoglobin concentration was measured by the method of Drabkin and Austin (89). 
In this method, 0.04 ml sample was pipetted into a test tube and 2.5 ml of Drabkin's 
solution was added. During the reaction, haemoglobin was first oxidized with 
potassium hexacyanoferrate (HI) to methaemoglobin which then reacted with 
! potassium cyanide to form cyanmethaemoglobin. After 10 min, the optical densities 
；V 
I of the samples were measured by a spectrophotometer at 540 nm and the results were 
compared with the standard curve to find out the concentration of the samples, j • “ 
Glomerular filtration rate was estimated, from inulin clearance. Quenching was 
corrected by external standard. Since the urine samples wi l l contain haemoglobin or 





Two way analysis of variance was used for comparison of urinary TCS 
excretion at different doses of TCS injection (p < 0.05). For comparing the effect 
of haemoglobin and lysozyme infusion on TCS excretion, one way analysis of 
variance followed by Scheffe multiple comparison test was used (p < 0.05). 
Multivariate analysis of variance was used for inter-group comparison of inulin 
clearance (p < 0.05). 
Result 
I 
{ In the first experiment, urinary recovery of TCS was only 0.29 士 0.06% 
when the smallest injection dose was used (0.375 mg/kg; Fig. 6.1) meaning that over 
95% of the administered dose could not be found in urine although kidney is the 
major organ of elimination. However, the percentage of urine TCS recovery increased 
tremendously when higher injection dose was used. I t could increase up to about 40% 
when 12 mg/kg TCS was injected and the curve gradually approached the plateau 
phase. Figure 6.2 showed the plasma concentration of TCS after different doses of 
drug injection. When the percentage of total TCS recovered in each 45 minute 
interval was calculated, the majority of the urine TCS (over 85%) was recovered in 
the first 45 minute after injection regardless of the doses used (Fig. 6.3). The 
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percentage decreased rapidly with time together with the plasma concentration of 
TCS. Finally only very little TCS was excreted (less than 5%) in the last 45 minute 
compared to the total TCS excreted. 
When77.5 ^Ulysozyme was infused and0.375 mg/kgTCS was injected, the 
percentage of TCS recovered in urine was significantly increased from 0.29 土 0.06% 
to 3.20 土 0.86%. Infusion of 77.5 ^ M stxoma-free haemoglobin further increased the 
TCS recovered in urine to 35.23 土 2.66% (Fig. 6.4). Haemoglobinuria were also 
observed. The plasma haemoglobin concentration was constant at about 1.0 ± 0 . 1 
g/1. 
I Figure 6.5 showed the inulin clearance of different groups of rats. Injection 
I of TCS caused a significant decrease in GFR throughout the entire experimental 
i period. Simultaneous infusion of haemoglobin led to a further decrease in GFR. 
However, there was no significant change in GFR compared with the control when 
lysozyme was infused with TCS injection. Injection of DX-TCS or infusion with 
lysozyme alone also did not altered the GFR when compared with the control. 
In the radioimmunoassay, addition of different concentrations of haemoglobin 
or lysozyme did not affect the percentage of total binding in the assay. 
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Fig.6.1 Percentage of the administered TCS recovered in urine during the 135 
min period after injection. The dosage used are 0.375 (N=13), 0.75 (N=6), 
1.5 叙=6) , 3 (N=7), and 12 mg/kg (N=4). Values are expressed as means 
土 SEM. 
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Fig. 6.2 The plasma TCS concentration at different time after injection of 
various doses of TCS. Values are expressed as means 士 SEM. 
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Fig. 6.4 Effect of infusing 77.5 jiiM lysozyme (N=12) or haemoglobin 
(N=14) at a rate of 3.4 ml/hr on urine TCS recovery. Trichosanthin was 
injected at a dose of 0.375 mg/kg. Values are expressed as means 土 SEM. 
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Fig. 6.5 Temporal profile of the inulin clearance in six groups of rat. Drug 
was injected at time zero. Infusion of saline, lysozyme, or haemoglobin 
started at 90 minutes before drug injection and continued throughout the 
experiment. Values are expressed as means 土 SEM. Only (i) TCS injection 
and saline infusion (ii) TCS injection and haemoglobin infusion showed a 




The present experimental data support that the filtered TCS was reabsorbed 
by the kidney. The first line of evidence was that the recovery of TCS in urine could 
I 
be increased by using higher injection dose. The percentage recovery also followed 
a dose dependent manner. I f there was no reabsorption of TCS in the kidney, the 
amount of TCS filtered would equal to the amount excreted and hence the amount 
recovered in urine. The amount of TCS filtered depend on both the glomerular 
I filtration rate and the plasma TCS concentration which equals to the total amount of 
drug injected divided by the distribution volume. Therefore, the percentage of TCS 
recovered in a certain period of time would equal to the amount of TCS filtered 
I 
divided by the total amount of TCS injected which subsequently result in a 
mathematical relationship independent of the dosage of TCS. As a consequent, the 
percentage of TCS recovered should remain the same regardless of different injection 
doses i f there is no tubular reabsorption. On the other hand, i f small injection dose 
was used, the kidney was able to reabsorb most of the filtered TCS resulting in low 
urine recovery. On the contrary, the injection of large amount of TCS exceeded the 
renal reabsorptive capacity of TCS so that a lot of TCS was spilt into the urine. For 
similar reasoning, a major part of the urine TCS was recovered in the first 45 min 
after injection for all of the injected doses. It was because in this period, the plasma 
TCS concentration and hence the filtered load was highest. This exceed the capacity 
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of the kidney to reabsorb TCS and therefore relatively large amount of TCS was 
recovered from the urine. Afterwards, the plasma concentration decreased rapidly and 
the kidney was capable to reabsorb most of the TCS. Indeed, the proximal tubular 
cells are capable of reabsorbing up to 0.2 mg/kg body weight of small molecular 
weight proteins in 1 hour (90). This quantity is in the same order of magnitude as the 
i amount of TCS administered. 
Concerning the mechanism of tubular TCS reabsorption, it is logical to assume 
I 
that TCS utilizes the common reabsorption process with other small molecular weight 
proteins. The body is unlikely to have a specific pathway for this exogenous protein 
which do not appear in the renal tubules in normal circumstances. Kidney is an 
important organ for the catabolism of most small molecular weight protein (e.g. 
lysozyme) (75,74,85) and also larger proteins such as albumin and haemoglobin (91). 
Proteins are reabsorbed by segregation into endocytotic vesicles at the apical border 
of tubular cells. The vesicles then migrate to the interior of the cells and fuse with 
lysosomes in which they are digested. The first step in endocytosis in the proximal 
tubule involves the binding of the positively-charged moiety of the protein to the 
negatively charged luminal membrane. Thus, this process can be inhibited by cationic 
but not anionic or neutral amino acids (75). Also, infusion of one protein can 
increase the excretion of another due to the sharing characteristic of the endocytotic 
process (86,87). 
74 
The competitive nature of TCS reabsorption can be demonstrated. Both the 
infusion of lysozyme and haemoglobin caused a significant increase in urinary TCS 
excretion. This enhancement effect is likely due to competition between the infused 
protein and TCS for the reabsorption process. This also implies that both lysozyme, 
I haemoglobin and TCS shares the common endocytotic mechanism which is rather 
j 




From the inulin clearance data, it seemed that both the reabsorption of TCS 
and haemoglobin into renal tubular cells caused the gross malfunction of the kidney 
as manifested by the reduction in GFR which is an index of renal damage. Hence, 
they were nephrotoxic when presented in the tubular cells. In fact, it has been shown 
previously that presence of haemoglobin in renal tubules would induce kidney damage 
(88). However, this nephrotoxic effect could be avoided i f we could prevent the 
reabsorption of TCS. Therefore, when DX-TCS was injected instead of TCS, GFR 
was the same as control because the conjugate was not able to pass through the 
glomerulus and reabsorbed. Simultaneous infusion of lysozyme also caused the GFR 
remained within the normal range probably by reducing its tubular reabsorption. 
Although lysozyme was also reabsorbed into tubular cells, it did not generate 
nephrotoxic effect. I t seems that the nephrotoxicity was related to the nature of the 
reabsorbed molecule that is present inside the tubular cells rather than the 
reabsorption process. Therefore, the damaging effect of TCS may be attributed to its 
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ribosome inactivating property which takes place inside the tubular cells. 
The precise relationship between tubular damage and the depression in 
glomerular filtration rate in this case was not known. However, it may attribute to the 
activation of the tubuloglomerular feedback mechanism of the kidney. The 
•I 
! tubuloglomerular feedback is a regulatory mechanism which tends to lower the 
li 
i； 
glomerular filtration rate whenever the solute delivery or solute concentration at the 
macula densa is raised (101, 102). After reabsorption of TCS and ribosome 
I inactivation had taken place, it might impair the sodium reabsorption of the tubular 
cells. I t would then result in an increase in macula densa flow and chloride delivery. 
Therefore, in order to prevent excessive salt and water losses, the kidney wil l initiate 
a response that involves afferent arteriolar constriction and decreased capillary 
permeability by contraction of mesangium. Consequently, a depression of glomerular 
filtration rate follows (103, 104). The damaging effect of TCS was very rapid and 
was most prominent at 90 minute after drug injection as reflected by the lowest 
glomerular filtration rate. This time interval was more or less similar to the time 
required for the physiologic effects of the steriod hormine aldosterone in which its 
action also includes cellular entry of the hormone and ultimately increasing the 
synthesis of new channel proteins that responsible for sodium reabsorption (107). 
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Chapter 7: Biological activities of Dextran-Trichosanthin 
The previous chapters described the coupling of dextran to TCS and the 
pharmacokinetic properties of the conjugate. The next critical step thus involves the 
characterization of the biological activity of the conjugate. I t is very important to 
i 
know whether the DX-TCS conjugates still retain biological activities of the parent 
compound. With this regard, different bioassays (both in vivo and in vitro) were 
performed to evaluate whether coupling of TCS to dextran would alter its original 
biological behaviour. 
Trichosanthin has wide spectrum of biological and pharmacological activities. 
An important one is the induction of mid term abortion (3,30,31). Hence, the in vivo 
bioassay selected was mid term abortifacient activity on pregnant mice. Other 
methods of evaluation includes in vitro bioassays in tissue culture. Trichosanthin is 
known to suppress the mitogenic effect on T and B lymphocytes (53,54), this 
immunosuppressive effect was compared between the native compound and the 
conjugate. Moreover, the anti-tumour activity of the conjugates was also evaluated 
using two different tumour cell lines (PU5-1.8 and H35). 
77 
Method 
The general procedures of the different bioassays were described in 
methodology (Chapter 2). Briefly, the evaluation of mid term abortifacient activity 
was done by injecting different concentrations of TCS (0.01-0.20 mg/25g) and DX-
TCS (0.01-0.40 mg/25g) intraperitoneally into mice on day 12 of pregnancy (PD 12). 
Mice were then autopsied on day 14 (PD 14) of pregnancy and the abortifacient effect 
.was examined. Control mice were injected either with normal saline solution or 
dextran solution. For the in vitro bioassays, the target cells (T and B lymphocytes, 
tumour cells) were treated with various concentrations of TCS or DX-TCS and 
cultured for 48-hr period. The degree of cell proliferation were then measured by 
determining the rate of tritiated thymidine incorporated into DNA. Results were 
expressed as % inhibition with reference to the control using the following formulae: 
^H-TdR incorporation in the presence of drug 
% inhibition = 1 X 100% 
^H-TdR incorporation in the absence of drug 
(control) 
In order to clarify that the effect of TCS or DX-TCS is inhibitory on proliferation 
rather than cytotoxicity, in a separate experiment, normal target ceUs were cultured 
with a high concentration (SOjiig/ml for mouse lymphocytes and lOO^g/ml for tumour 
cells) of drugs for 2 days. The cell viability after incubation was assessed by trypan 
blue dye exclusion method (76). 
78 
Statistical analysis 
One way analysis of variance followed by Scheffe multiple comparison test 









L in vivo bioassay - Midterm abortifacient activity 
The midterm abortifacient activity of TCS and its conjugates on pregnant mice 
was done and the results were summarized in Table 7.1. Mice were considered 
aborted when the no. of dead fetuses exceeded 50% of the total implantation sites. 
Results showed that TCS has potent midterm abortifacient activity. A single 
intraperitoneal (i.p.) TCS injection of as little as 0.01 mg/25 g body weight (B.W.) 
elicited 67% midterm abortion. DX-TCS, like its parent compound, could also induce 
‘ midterm abortion. The potency of the conjugates in inducing midterm abortion was 
decreased. No abortifacient effect was detected at the dose of 0.05 mg/25 g B.W. 
DX-TCS while TCS injection of this dose could induce 100% midterm abortion. 
However, 100% midterm abortion was attained only when the injection dose of DX-
TCS was increased to 0.40 mg/25 g B.W. For the control mice, injection of either 
normal saline solution or dextran solution showed no abortifacient effect. The toxicity 
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of the conjugates as judged from the mortality rate of the treated mice was also found 
to be decreased. A single dose of 0.10 mg/25 g B.W. TCS was toxic and about 33% 
of the treated mice was dead. In contrast, no death occurred in the treated mice 
received DX-TCS injection even when four times as much DX-TCS was used. Figure 
7.2 is a photograph showing the gross morphology of the uterine implantation sites 
j 
i of a normal and a aborted mice while Fig. 7.3 shows a more closer examination of 
i • … ‘ j 
the normal and dead fetuses, 
i • ‘ 
I 
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2. in vitro bioassay 
(A) Mitogen induced lymphocyte transformation 
Figure 7.4 - 7.6 showed the effect of TCS or DX-TCS on the % inhibition of 
tritiated thymidine uptake at various drug concentrations. The mitogenic responses of 
lymphocytes induced by Con A, PHA and LPS were inhibited by TCS as shown by 
the decreased incorporation of thymidine with increasing drug concentration. The 
mitogenic response was greatly suppressed ( > 90%) at TCS concentration of 50 
/xg/ml and was clearly dose dependent. When comparing the three figures, TCS 
appeared to be more inhibitory to the PHA response according to their respective IC50 
which refers to the concentration of drug that cause 50% inhibition. Figure 7.4 shows 
that significant suppression was seen at a protein concentration of as low as 0.1 
pig/ml It took only 5 /ig/ml of TCS to attain 50% inhibition which was less than that 





！ induce significant inhibition. Fig. 7.11 showed the response of another cell line (rat 
hepatoma cells) to TCS and DX-TCS. From the graph, it was found that hepatoma 
cells were relatively resistant to the cytostatic effect of TCS with the approximate ID50 
of 10 pLg/ml The ID50 of DX-TCS was 50 /ig/ml. However, both the dextran and 
DX-TCS produced similar cytostatic effect on the cells. 
. 82 
(A) TCS 
Dose No. of No. of dead fetuses/ % of No. of 
(mg/25g) treated No. of implantation aborted dead 
mice sites mice* mice 
0.20 7 40/40 (100%) 100% 5 -
0.10 12 111/111 (100%) 100% 4 
0.05 4 55/55 (100%) 100% 0 
0.02 4 51/51 (100%) 100% 0 
0.01 3 31/38 (38%) 67% 0 
(B) Dx-TCS 
Dose No. of No. of dead fetuses/ % of No. of 
(mg/25g) treated No. of implantation aborted dead 
mice sites mice* mice 
0.40 7 102/102 (100%) 100% Q 
0.20 10 129/143 (90%) 90% 0 
0.10 11 115/168 (68%) 55% 0 
0.05 6 7/86 (8%) 0% 0 
0.02 5 13/68 (19%) 0% 0 
0.01 3 9/43 (21%) 0% 0 
(C) Control 
Normal Saline/ No. of No. of dead fetuses/ % of No. of 
Dextran Solution treated No. of implantation aborted dead 
mice sites mice* mice 
Normal Saline 18 14/261 (5%) 0% 0 
Dx(0,2mg/25g) 9 4/126 (3%) 0% 0 
Dx(0.4mg/25g) 2 3/16 (19%) 0% 0 
*Mice was considered aborted when the no. of dead fetuses exceeded 50% of the total 
implantation sites. 
Table 7.1 Midterm abortifacient activity of TCS and DX-TCS on pregnant mice. 
83 
r产糊 
Fig. 7.3 A photograph showing the gross morphology of the uterine 
implantation sites of a normal (left) and a aborted mice (right). 
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Fig. 7.4 A photograph showing the normal fetuses (1) and dead fetuses (2) 
dissected out from the uterine implantation sites. 
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Fig. 7.4 Effect of TCS, DX-TCS and dextran on Con A-induced lymphocyte 
transformation. Concentrations of TCS and dextran were adjusted for 
individual components. Values are expressed as means 土 SEM (N=4). 
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Fig. 7.5 Effect of TCS, DX-TCS and dextran on PHA A-induced lymphocyte 
transformation. Concentrations of TCS and dextran were adjusted for 
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Fig. 7.6 Effect of TCS, DX-TCS and dextran on LPS-induced lymphocyte 
transformation. Concentrations of TCS and dextran were adjusted for 
individual components. Values are expressed as means 士 SEM (N=4). 
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Drug Conc.(/ig/inl) % of cells surviving after 48 hrs 
Control 0 fxg/ml 92.72 土 0.74 
TCS 50 jLcg/ml 90.66 士 1.53 
DX-TCS 50 ^g/ml 86.24 土 0.65 
Dextran 50 /xg/ml 83.44 士 0.90 
Table 7.7 The effect of TCS, DX-TCS and dextran on the % viability of 
lymphoyctes. No 2 groups are significantly different at p=0.05 using oneway analysis 
of variance followed by Scheffe Multiple Comparison test (N=6). 
* 
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Drug Conc.(Mg/ml) % of cells surviving after 48 hrs 
Control 0 ^g/ml 92.51 士 2.80 
TCS 100 jug/ml 86.67 士 5.60 
DX-TCS 100 Mg/ml 98.18 士 1.82 
Dextran 100 /^g/ml 97.33 士 2.67 
Table 7.8 The effect of TCS, DX-TCS and dextran on the % viability of PUS cells. 
No 2 groups are significantly different at p=0.05 using oneway analysis of variance 
followed by Scheffe Multiple Comparison test (N=6). 
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Drug Conc.()Ltg/ml) % of cells surviving after 48 hrs 
Control 0 fxg/ml 96.18 士 1.98 
TCS 100 Atg/ml 93.88 土 2.39 
DX-TCS 100 /xg/ml 95.68 士 1.00 
Dextran 100 fig/mi 93.55 士 3.29 
Table 7.9 The effect of TCS, DX-TCS and dextran on the % viability of hepatoma 
cells. No 2 groups are significantly different at p=0.05 using oneway analysis of 
variance followed by Scheffe Multiple Comparison test (N=6). 
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Fig. 7.10 The cytostatic effect of TCS, DX-TCS and dextran on the growth 
of PUS cells after incubating with the drugs for 48 hr. Values are expressed 
as means 土 SEM (N=4). 
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Fig. 7.11 The cytostatic effect of TCS, DX-TCS and dextran on the growth 
of hepatoma cells after incubating with the drugs for 48 hr. Values are 
expressed as means 土 SEM (N=4). 
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Discussion 
The biological activities of DX-TCS conjugate as determined by both in vivo 
and in vitro bioassays were well preserved. However, there was a general decrease 
in potency when compared to the native compound. For example, in midterm 
abortion, it took twenty times as much DX-TCS than TCS to induce 100% abortion. 
The ability of DX-TCS to inhibit Con A and PHA induced lymphoproliferative 
response was decreased. DX-TCS was six times less potent than its native compound 
in inhibiting the growth of PUS cells as estimated from their respective ID50. 
The detail mechanism of this decrease in potency was still unknown at this 
stage. However, the most logical speculation is that the stearic rigidity acquired by 
the dextran conjugate is responsible for the decreased pharmacological activity. Loss 
of activity can also due to the blocking of active sites during the coupling reaction. 
Trichosanthin is a single chain Type I RIP which has to get into the cells to exert its 
inhibitory action on protein synthesis (18,19,20). Therefore, TCS is most sensitive 
to cells which are phagocytotic in nature. For those target cells (e.g. PUS cells, 
syncytiotrophoblast in the placenta) which are phagocytotic in nature, DX-TCS 
conjugate is still able to enter these type of cells where it exerts its action. As a 
consequence, the biological activities can be preserved although with decreased 
potency. • 
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In the study of anti-tumour activity, PUS cells were more sensitive than 
hepatoma cells to the cytostatic action of the drugs as evaluated from their respective 
ID50. This is probably due to the fact that PUS is a macrophage-like cell line and was 
expected to possess phagocytotic ability. This would facilitate the internalization of 
the drugs into the cell which was thought to be a prerequisite for the inhibitory action 
on tumour growth. In fact, TCS has been used therapeutically for the treatment of 
certain types of trophoblastic tumours (37). 
Similarly, the ID50 of DX-TCS in inhibiting PUS and hepatoma cells were 30 
and 50 /xg/ml respectively indicating that the conjugate was less effective against 
hepatoma cells. Since dextran also produced similar inhibitory effect on hepatoma 
cells, the anti-tumour activity could either due to the TCS component, dextran 
component or both. Nonetheless, the protein component of DX-TCS was less 
effective in inhibiting hepatoma cells than PUS cells because of the increased ID50 and 
some of its inhibitory effect might attribute to the dextran component. Therefore, 
coupling of TCS to dextran seems to further reduce its cellular entry into the non-
phagocytotic cells. This is probably due to the inability of the larger complex to enter 
this type of cells which are non-phagocytotic in nature. On the contrary, coupling of 
TCS to dextran did not affect the phagocytosis of the PUS cells although the 
molecular size was expanded. 
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Apart from the potency of the conjugate, its toxicity was also decreased. In 
the midterm abortifacient activity, a dose of as little as 0.1 mg/25g B.W. induced 
33% mortality whereas four times as much DX-TCS (0.4 mg/25g) did not cause any 
death. With regard to the effect of coupling on cellular entry of TCS, the reduction 
in toxicity may due to the inability of the conjugate to enter other normal cells. 
Therefore, coupling may probably channel the conjugate to the phagocytotic target 
cells while reducing the non-specific damaging on other cells. This reduction in 
toxicity is indeed valuable in improving the therapeutic usage of the drug. 
In conclusion, after coupling of TCS to dextran, the product is still 
biologically active. It retained most of the biological activities of the parent compound 
evaluated by different bioassays, both in vivo and in vitro. Although the effectiveness 
was decreased, its toxicity was also decreased suggesting an improved therapeutic 
usage of the drug after modification. 
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Chapter 8: Immunological activities of DX-TCS 
Previous chapters described that DX-TCS has a longer biological half-life than 
its native compound with reduced biological activities and toxicity. Base on the 
clinical experience in China, extensive clinical usage of TCS is limited by its allergic 
side effect (e.g immediate hypersensitivity; 93,94). For this reason, skin test has to 
be done in these patients prior to the administration of this drug. In this study, an 
attempt is made to examine whether coupling TCS to dextran can reduce its 
immunogenicity through the blocking of epitope(s) on the molecule. 
After modification, the immunological activities of DX-TCS was examined by 
two different ways. Firstly, the binding of DX-TCS to TCS specific antibody is 
examined by radioimmunoassay. This is followed by a binding study using DX-TCS 
with the dextran moiety digested by the enzyme dextranase to see whether the dextran 
component of the DX-TCS molecule is responsible for the changes of binding affinity. 
Secondly, TCS, DX-TCS or dextran with/or without adjuvant were used to immunize 
the mice to examine the potency of these antigens in inducing IgG and IgE production 
by using an antibody capture approach with enzyme linked immunosorbent assay 
(ELISA). These two antibodies were chosen because they are important in 
determining the antigenicity of a compound. Immunoglobulin G is the major antibody 
of secondary immune response which is characterized by a sustained high titxe of 
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antibodies. On the other hand, IgE takes an important role in mediating immediate 
hypersensitivity including anaphylaxis which may result in death of the animal. 
Method 
The binding characteristics of DX-TCS to TCS antibodies was firstly examined 
using a radioimmunoassay procedure in which DX-TCS standards instead of TCS 
were used. During the incubation, iodinated TCS competes with DX-TCS to bind to 
the TCS specific antibodies. This is followed by the examination of the binding 
characteristics of DX-TCS after the dextran moiety being digested by dextranase. 
(Dextranase is the enzyme that would hydrolyse the a-1—6 glycosidic linkage of 
dextran.) This was done by incubating DX-TCS with dextranase for 20 hr at 36°C. 
In the control experiment, dextran, dextranase or both were added to the 
radioimmunoassay standard tubes to see whether these substances would interfere the 
antibody-antigen reaction. 
In the immunogenicity study of TCS, DX-TCS and dextran, mice (C57 
BL/6N) were divided into 4 groups. The first 3 groups were immunized with (i) 10 
fjLg TCS (ii) an amount of DX-TCS equivalent to 10 ng TCS (iii) dextran equivalent 
to the amount present in DX-TCS. The fourth group served as control with no 
immunization. Each antigen with complete Freund's adjuvant (1:1 v/v) was given to 
« 
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a group of mice followed by 2 booster injections of the same antigen (with Freund's 
incomplete adjuvant) at 3 and 2 weeks afterwards. After the immunization procedure, 
TCS specific antibodies were detected by ELISA using antibodies capture approach. 
Briefly, TCS, DX-TCS or dextran was coated onto the microtitre plates. This was 
followed by blocking of excess binding sites and then incubated with diluted mouse 
sera. The IgG and IgE present in the mouse sera was detected by sheep anti-mouse 
IgG-HRP or sheep anti-mouse IgE and Donkey anti-sheep IgG-HRP respectively. 
Eventually, the bound enzyme (HRP) is visualized by the addition of chromogen 
(OPD) which is a colourless substrate that acts on the enzyme to produce a coloured 
end-product. The amount of antibody was then measured by assessing the amount of 
end-product through optical density scanning of the microtitre plate. The data 
obtained are quantified by comparing the respective litre of the mouse sera. For IgG 
quantitation, litre is defined as the greatest dilution giving an optical density of 0.8 
unit. For IgE quantitation, titre is defined as the greatest dilution giving an optical 
density of 0.2 unit. The intra-assay coefficient of variance was determined by 
measuring the same serum sample twelve times in one assay. The inter-assay 
coefficient of variance was determined by measuring the same serum sample in 
triplicate in one run and repeated on 5 different assays. 
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Result 
1. Binding activity of DX-TCS conjugate to TCS antibodies 
Figure 8.1 shows the effect of dextran and/or dextranase on TCS competitive 
binding curve. The radioimmunoassay for TCS was not affected by the presence of 
dextran, dextranase or both. When compared the binding curve of DX-TCS to that 
of TCS, it shifted in a parallel manner to the right (Fig. 8.2) suggesting a decrease 
in affinity of DX-TCS to TCS antibodies. However, the binding affinity of DX-TCS 
was increased partially when the dextran moiety was digested by dextranase as shown 
by a back shift of the binding curve towards that of TCS. 
2. Immunogenicity of TCS, DX-TCS and dextran 
(a) With adjuvant 
Before the assay was used to test the different mouse sera, its validity was 
checked by using hyperimmune mouse sera as positive control which has been 
characterized by radioimmunoassay. Result indicated that the TCS specific IgG and 
IgE could be detected by the TCS coated microtitre plate in this assay system and 
dilution curves were obtained as in Fig. 8.3. 
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Figure 8 .4 -8 .6 shows the serial dilution curves of different mouse sera for 
IgG determination on TCS, DX-TCS and dextran coated ELISA plate respectively. 
The litres of different mouse sera performed in various ELISA plate coating were 
compared semi-quantitatively and summarized in Table 8.9a. Several features are 
evident from this table. First, mice immunized with TCS resulted in a titre of two-
fold higher than those of mice immunized with DX-TCS on TCS coated microtitre 
plate. Second, when the sera were tested on DX-TCS coated microtitre plate, DX-
TCS immunization resulted in two-fold more IgG bound onto the plate than that of 
TCS. Third, when the ability of the antigen in generating antibodies against itself was 
compared (i.e. TCS immunized sera on TCS coated plate compared with DX-TCS 
immunized sera on DX-TCS plate), DX-TCS immunization was found to produce 
approximately four-fold lower IgG than those of mice immunized with TCS. Fourth, 
the control mice and the mice immunized with dextran showed no immune response 
against TCS, DX-TCS or dextran. Finally, when mouse sera were tested on the 
dextran coated microtitre plate, only the mice received DX-TCS injection elicited 
trace amount of anti-dextran IgG. 
Apart from the IgG response, the immunogenicity of TCS, DX-TCS and 
dextran in producing IgE was also performed and the respective serial dilution curves 
were shown in Figure 8.7 - 8.8. The comparisons between different combinations 
were summarized in Table 8.9b. On TCS coated microtitre plate, the sera of mice 
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immunized with TCS showed about eight-fold higher titre than did the sera of mice 
immunized with DX-TCS. Similar to that of IgG, there was two-fold difference in 
titre when the sera were tested on DX-TCS coated microtitre plate. When the ability 
of the antigen in generating antibodies against itself was compared (i.e. TCS 
immunized sera on TCS coated plate compared with DX-TCS immunized sera on DX-
TCS plate), DX-TCS immunization was found to produce approximately four-fold 
lower IgG than those of mice immunized with TCS. Moreover, all the mice showed 
negative IgE response towards dextran. 
The intra-assay coefficient of variance and the inter-assay coefficient of 
variance estimated for different assays were summarized in Table 8.10. 
(b) Without adjuvant 
Generally, the immune response was weaker as shown by a lower OD value 
when adjuvant was not used in immunizing the mice and the resulting pattern was 
also different. In the production of IgG, the serial dilution curve of TCS showed no 
significant difference with that of DX-TCS on either TCS or DX-TCS coated 
microtitre plate (Fig. 8.11 and 8.12). Similar to that with adjuvant, only DX-TCS 
injection produced trace amount of anti-dextran IgG (Fig. 8.13). 
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In the IgE response, the two groups were not significantly different from each 
other on the TCS coated microtitre plate (Fig. 8.14). On the contrary, DX-TCS 
immunization resulted in a four-fold higher IgE titre compared to TCS injection in 
DX-TCS coated microtitre plate (Fig. 8.15). The results for different combinations 
were simplified and summarized in Table 8.16. When the competence of different 
antigen in eliciting their specific antibodies was compared (i.e. TCS immunized sera 
on TCS coated plate compared with DX-TCS immunized sera on DX-TCS plate), 
DX-TCS immunization was found to produce approximately four-fold lower IgG and 
two-fold higher IgE than those of mice immunized with TCS. Moreover, all the mice 
failed to elicit anti-dextran IgE. 
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Fig. 8.3 Dilution curves of hyperimmune mouse sera. TCS specific IgG 
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Fig. 8.7 Two-fold serial dilution curves of different mouse sera on TCS 
coated microtitre plate for IgE determination (with adjuvant). Values are 
expressed as means 土 SEM (TCS, N=4; DX-TCS, N=5). 
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Fig. 8.8 Two-fold serial dilution curves of different mouse sera on DX-TCS 
coated microtitre plate for IgE determination (with adjuvant). Values are 
expressed as means 土 SEM (TCS, N=4; DX-TCS, N=5) . 




TCS DX-TCS Dextran 
(1) TCS + + + + + -+ + + + 
(2) DX-TCS + + + + t ^ 
(3) Dextran 一 一 _ 
(4) Control 一 _ 一 
(b) IgE 
COATING 
TCS DX-TCS Dextran 
(1) TCS + + + + + -
+ + + + 
(2) DX-TCS j- -
(3) Dextran = 
(4) Control _ _ _ _ _ 
Table 8.9 A summary of relative quantity of IgG (upper) and IgE (lower) obtained 
from Fig. 8.4 - 8.8 in which different mouse sera (with adjuvant) were tested on 
various antigen coated microtitre plate. 
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(a) Intra-assay coefficient of variance 
— Coating 
TCS DX-TCS Dextran 
IgG 3.82% 2.52% 3.66% 
IgE 3.35% 2.90% ^ 
(b) Inter-assay coefficient of variance 
Coating 
TCS DX-TCS Dextran 
IgG 7.61% 3.66% 3.66% 
IgE 4.15% 6.27% ^ 
Table 8.10 Intra-assay (a) and inter-assay (b) coefficient of variances in different 
enzyme linked immunosorbent assays. 
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Fig. 8.11 Two-fold serial dilution curves of different mouse sera on TCS 
coated microtitre plate for IgG determination (without adjuvant). Values are 
expressed as means 士 SEM (TCS，N二5; DX-TCS, N=5) . 
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Fig. 8.12 Two-fold serial dilution curves of different mouse sera on DX-TCS 
coated microtitre plate for IgG determination (without adjuvant). Values are 
expressed as means 士 SEM (TCS,N=5; DX-TCS, N=5). 
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Fig. 8.13 Two-fold serial dilution curves of different mouse sera on dextran 
coated microtitre plate for IgG determination (without adjuvant). Values are 
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Fig. 8.14 Two-fold serial dilution curves of different mouse sera on TCS 
coated microtitre plate for IgE determination (without adjuvant). Values are 
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Fig. 8.15 Two-fold serial dilution curves of different mouse sera on DX-TCS 
coated microtitre plate for IgE determination (without adjuvant). Values are 





TCS DX-TCS Dextran 
(1) TCS + + + + + ： 
(2) DX-TCS + + + + + trace 
(3) Dextran 
(4) Control 一 二 — 
(b) IgE 
COATING 
TCS DX-TCS Dextran 
(1) TCS + + + ： 
(2) DX-TCS + + + + -
(3) Dextran : 
(4) Control _ 丨 _ 
Table 8.16 A summary of relative quantity of IgG (upper) and IgE (lower) obtained 
from Fig. 8.11 - 8.15 in which different mouse sera (without adjuvant) were tested 




Coupling of a molecule to another macromolecule not only prevent its rapid 
elimination from the circulation, sometimes this approach also has the advantage of 
reducing the antigenic activity of the parent compound (61,62,63,71). In the 
competitive radioimmunoassay, the binding curve of DX-TCS to TCS antibodies 
shifted in a parallel manner to the right of the TCS binding curve. This suggests 
specific binding of TCS antibodies to DX-TCS but with decreased affinity relative to 
TCS. This is likely due to the steric hindrance of dextran on the TCS molecule so 
that some of the antigenic determinants on TCS are not accessible by the antibodies. 
However, the antibodies can still recognize the complex because some of the epitopes 
were not masked by dextran or some of the antibodies can possibly overcome the 
steric hindrance by displacing the flexible side chain away and binds to the complex. 
This point is further supported by the observation that an increase in DX-TCS binding 
affinity towards that of TCS after the dextran moiety was digested by dextranase. 
Free dextran and/or dextranase do not seem to affect the radioimmunoassay. 
Nevertheless, this binding activities could only be partially reversed. This may be due 
to the incomplete digestion of dextran by dextranase or the inability of the enzyme 




Apart from the study of antibodies binding characteristic of DX-TCS, its 
immunogenicity was also tested and compared with the native compound. Numerous 
examples have shown that after coupling the protein molecule to dextran, the antigen 
reactivity was lowered (61,62,63,71). In the present study, both TCS and DX-TCS 
were not different from each other in inducing TCS specific IgG and IgE when no 
adjuvant was used. However, when the immune system was stimulated by using 
adjuvant which is a non-specific immunostimulator, substantial difference was seen 
in the immunogenicity between TCS and DX-TCS in inducing TCS specific 
antibodies. This phenomena was more prominent in IgE production in which a eight 
fold difference was observed. This suggests coupling sterically protect TCS from 
immune recognition. During the process, the antigen is first taken up by the antigen 
presenting cells. The partially degraded antigen is then presented on the cell surface 
in associated with MHC molecules. This is followed by the. T cell recognition in 
• -
which its help is probably necessary for a strong immune response. I f the dextran 
moiety is small, T and B cell collaboration is allowed to take place and would result 
in strong immune response. However, a large dextran moiety probably interferes with 
the recognition and hence result in a weaker response. Indeed, Sepp^a el al showed 
that the decreased immunogenicity was related to the size of dextran molecule used. 
When small size dextran molecule (e.g. 1 to 4 kDa) was used to couple the protein, 
a stronger immunogenic response was elicited. However, when the size of dextran 
was increased to 40 kDa, the antigenicity was greatly reduced (62). 
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Nevertheless, the most important purpose of this study is to see whether 
coupling can actually reduce the immunogenicity of the compound. This can be 
concluded from the comparison between TCS sera on TCS microtitre plate and DX-
TCS sera on DX-TCS microtitre plate. When adjuvant was used, DX-TCS was found 
to elicit much less IgG and IgE that could bind to the conjugate than that of TCS. 
Therefore, coupling seems to has the beneficial effect in reducing the immunogenicity 
of the compound in terms of the production of IgG and IgE. Also, one interesting 
finding is that the IgG elicited by DX-TCS in fact binds more readily to TCS plate 
than to DX-TCS plate. This suggests that some of the TCS specific IgG generated by 
DX-TCS immunization could not react with the conjugate probably due to the 
masking of the epitope(s) by dextran in the intact conformation of DX-TCS. This is 
analogous to the，canyon hypothesis, applied to the construction of HIV vaccine. In 
this hypothesis, it suggests that the binding site of the epitope may be inaccessible to 
the antibodies generated in the immune response due to steric hinderance. It is 
because the binding site recognized by the antibodies may be physically located in a 
deep cleft, or groove, surrounded by steep walls that made the antigen-antibody 
interaction difficult (105). 
Trace amount of the antibodies generated after DX-TCS injection (with 
adjuvant) was directed towards the dextran component as shown by a positive result 
on the dextran coated microtitre plate. Normally dextran is non-immunogenic in this 
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sixain of mice since injection of dextran alone failed to produce anti-dextran 
antibodies. However, the production of anti-dextran antibodies by the protein 
conjugate of dextran was due to the haptenic effect with the help of T lymphocytes. 
In summary, the conjugate was shown to possess lower antigen reactivity as 
demonstrated by generating less DX-TCS specific IgG and IgE when compared to the 
parent compound. Therefore, DX-TCS is more superior to TCS in this aspect and 
may reduce the risk of hypersensitivity reactions when giving to the patients. 
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Chapter 9: General Discussion 
Trichosanthin (TCS) is a purified plant protein isolated from the root tubers 
of Trichosanthes kirilowii (1,2,3). It possess wide range of biological and 
pharmacological activities. In China, TCS has been used in the treatment of ectopic 
pregnancy, hydatidiform mole, choriocarcinoma and mid-term abortion (5,6,7). The 
mechanism is believed to be mediated through its ribosome inactivating property 
(18,19,20). Recently, it was shown that TCS could inhibit the replication of human 
immunodeficiency virus (fflV-1) in vitro (47,48,49). Despite all these therapeutic 
applications of the protein, its usage is hampered by two major limitations. First, TCS 
is a small molecular weight protein (26 kDa) which can be easily filtered through the 
kidney and lost in urine. This means that patients have to receive frequent repeated 
doses in order to attain a certain plasma concentration of the drug. This is 
inconvenient to the patients and repeated doses would also increase the risk of 
hypersensitivity response. Second, TCS itself is antigenic and cause anaphylaxis in 
some patients (93,94). In view of these shortcomings, attempt has been made to 
increase the circulatory survival of TCS and to minimize its allergic side effect 
simultaneously. The approach is to couple the TCS molecule to a soluble 
biocompatible polysaccharide dextran T40. The molecular size wil l be larger and the 
complex can escape glomerular filtration. Steric hinderance might mask some epitopic 
site and reduce antigenicity of the molecule. 
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This study can be divided into three major parts; (1) pharmacokinetic study 
of TCS and its conjugate; (2) biological evaluation of DX-TCS and (3) immunological 
study of DX-TCS. To start this study, a sensitive detection method has to be 
developed to quantify TCS specifically. For this purpose, a radioimmunoassay was 
successfully developed to detect TCS in plasma and urine in nanogram range. In the 
pharmacokinetic study, kidney was found to be the major organ of TCS elimination 
leading to very short plasma half-life of the protein. Coupling of TCS to dextran was 
achieved by the periodate oxidation method (or dialdehyde method). After coupling, 
the conjugate has a much reduced renal and non-renal clearance rate due to the 
expanded molecular size. As a consequent, lesser dosage of the drug which is toxic 
. i n nature may be used. It may also avoid the requirement of repeated doses and hence 
. reduces the risk of hypersensitivity reaction. It was also found that TCS was 
reabsorbed by renal tubular cells. The reabsorption process is saturable and is likely 
to be the same as the common endocytotic process for other low molecular weight 
proteins. Excretion of TCS could be increased by simultaneous infusion of another 
filterable proteins such as lysozyme or haemoglobin. 
After injection of TCS, there was a significant decrease in glomerular 
filtration rate (GFR) suggesting renal toxicity. However, it is possible that GFR did 
not change significantly after injection of DX-TCS. The entry of TCS into renal 
tubular cell cause damage. I f it can be prevented form reabsorption, renal toxicity can 
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be avoided. Therefore, coupling of TCS to dextran not only prolonged the plasma 
half-life, it also served to prevent renal toxicity. 
The DX-TCS conjugate would not be useful i f it lost its activity. Therefore it 
is essential to evaluate the biological activity of the conjugate. When compared to the 
native compound, the biological activities were well preserved as manifested by the 
mid-term abortifacient activity, anti-tumour activity and its immunosuppressive 
ability. However, the potency of the complex was decreased. This may be due to the 
blocking of active site(s) by dextran molecule or the conformation of the active site(s) 
has been altered after modification. In spite of this, the toxicity of TCS was also 
decreased as seen in a reduced mortality rate in the treated pregnant mice and this 
further improved the therapeutic usage of the drug. Evidence suggest that after 
coupling the cellular entry of DX-TCS into non-phagocytotic cells was impaired. 
Reduction in toxicity may due to the cellular penetration of the conjugate was limited 
to those of the phagocytotic target cells but not other normal cells. 
As described earlier, one of the limitations of TCS is its antigenic side effect. 
Coupling may have the advantage of sterically protect the molecule from immune 
recognition. In fact, this was demonstrated by the following two findings. Firstly, in 
the antibody binding study of DX-TCS, the binding affinity of the conjugate towards 
TCS antibodies was decreased. Secondly, in the immunogenicity study, DX-TCS was 
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shown to elicit less IgG and IgE that react with the complex when compared with the 
native molecule. Therefore, it could be concluded that the conjugate has reduced 
antigenicity when compared to the native compound. This further improves the 
therapeutic usage of the drug by reducing the risk of developing hypersensitivity. 
Finally, for the future follow-up research, several extended studies may be 
performed. The toxicity of TCS was decreased after coupling to dextran. This may 
be related to the difference in cellular penetration ability of DX-TCS to phagocytotic 
and non-phagocytotic cells. Therefore, in order to substantiate our hypothesis that the 
conjugate, like its parent compound is still able to enter the target cells to achieve its 
action, it is essential to delineate the detail mechanism of cellular entry of TCS and 
its conjugate. Up to now, very little is known about the phenomena of cellular 
penetration and kinetics of the single chain ribosome inactivating protein. Therefore, 
by applying the fluorescence imaging technique and electron-microscopic 
immunocytochemistry, the process of penetration between native and modified 
compound on phagocytotic and non-phagocytotic cells can be compared. Moreover, 
another setback of this coupling method is that we do not know the exact position that 
the dextran binds to the TCS molecule. This wi l l lead to the production of a 
population of conjugates with the dextran binding to different active or immunogenic 
site(s) on the molecule. By using another method of coupling known as the alkylation 
method, the dextran can bind specifically to the sulfhydryl residue on the protein 
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molecule. Although the native TCS molecule lacks the sulfhydryl group for coupling, 
it may prove possibe to induce a site mutation on the TCS gene which has been 
recently cloned so that the new recombinant TCS possess the amino acid cysteine (and 
hence sulfhydryl group) on the surface of the molecule. Therefore by combining the 
present approach with the advent of molecular biology, we can specifically attach the 
dextran to different position and this helps to elucidate the exact location of active and 
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